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Abstract 
Interactions between Stem Cell Factor (SCF) and c-Kit are critical in maintaining β-cell 
survival and function. VEGF-A, essential in facilitating islet vasculature formation, is 
secreted by β-cells. This work investigates the mechanisms by which c-Kit regulates VEGF-
A production in β-cells, using a rat insulinoma (INS-1) cell line as an in vitro model. Cells 
were treated with recombinant hSCF or cultured with c-Kit (r) siRNA for 72 h. VEGF-A 
accumulation in the culture medium was measured by ELISA, while qRT-PCR, western blot, 
and immunofluorescence analyses were also performed. SCF augmented VEGF-A 
production in a time-dependent (p < 0.05 vs. control at 6 h and 24 h), and dose-dependent 
manner (p < 0.01 vs. control at 30-100 ng/mL). SCF stimulation increased phosphorylation 
of proteins along the PI3K/Akt/mTOR pathway (p < 0.05 vs. control groups), and decreased 
phosphorylation following siRNA treatment. Our results indicate that c-Kit exerts a 
regulatory effect on VEGF-A production in β-cells. 
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Chapter 1  
1 Introduction 
1.1 Significance of the Study 
Diabetes mellitus (DM) is a chronic condition characterized by loss of glucose 
homeostasis that results most commonly from autoimmune attack on β-cells in type 1 
DM (~10% of DM cases), peripheral tissue insulin resistance in type 2 DM (~90% of DM 
cases), or insulin receptor dysfunction during pregnancy in gestational DM. Patients 
suffering from type 1 or 2 DM commonly develop co-morbidities including 
cardiovascular disease, peripheral neuropathy, and nephropathy. Current treatment of 
diabetes includes an array of medications that increase insulin secretion and sensitivity as 
well as injecting exogenous insulin. These methods of treatment, however, are limited in 
their capacity to properly manage glucose homeostasis when faced with the progression 
of insulin resistance characteristic of DM pathology. Advancements in medical science 
have led to a focus on islet transplantation as a promising approach in curing diabetics. 
Yet, this procedure is still riddled with issues, with a reported 10% of total patients 
remaining free of daily insulin supplementation after a period of five years (Ryan et al., 
2005). One of the main obstacles surrounding islet transplantation is not only the limited 
supply of donor islets, but also the maintenance of islet health, including islet vasculature. 
Previous studies performed on cell types derived from a variety of tissue, including 
keloid fibroblasts, human mast cells, melanocytes, and small cell lung cancer cells, 
suggest that c-Kit receptor activation may be linked to regulation of hypoxia inducible 
factor-1α (HIF-1α), a transcription factor that is instrumental in the production of 
vascular endothelial growth factor-A (VEGF-A). VEGF-A is widely recognized as one of 
the most important proangiogenic factors in various murine models (Litz et al., 2006; 
Zhang et al., 2006; Monsel et al., 2010). 
This work seeks to provide evidence supporting that activation of c-Kit by its ligand, 
stem cell factor (SCF), in vitro, stimulates HIF-1α-mediated production of VEGF-A via 
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the PI3K/Akt/mTOR pathway, previously identified to be activated both in vitro and in 
vivo by c-Kit ligand-binding (Li et al., 2006; Li et al., 2007; Feng et al., 2012b). This 
study aims to further explore a basis for c-Kit as a potential cell-based therapeutic target, 
particularly for pro-angiogenic signaling-aided reconstruction of a dense, fenestrated 
capillary network that islets require in maintaining function and survival. Previous studies 
in our laboratory have shown that SCF immunoreactivity in the developing human 
pancreas was found in the duct regions and scattered throughout the fetal pancreas, 
including endocrine cells (Li et al., 2006), and SCF mRNA and protein levels was 
detected in the isolated mouse islets (Feng et al., 2012). 
1.2 The Pancreas 
The pancreas is a “dual organ” consisting of two major compartments: exocrine and 
endocrine, composed primarily of exocrine acinar cells, endocrine cells, and ductal cells, 
as well as a high degree of vascularisation in the endocrine compartment (Moore and 
Dalley, 1999). Most studies on normal insulin secretion and pancreatic development have 
utilized rodent islets or clonal cell lines, which have been proven to develop and respond 
to insulin secretagogues similarly to human islets, thus providing an apt model for studies 
on endocrine cell function and structure (MacDonald et al., 2011). Conversely, clonal cell 
lines have their limitations, as they are succeptible to transformation and alteration of 
genotype over time of the culture and must be periodically assessed for function in order 
to rule out allelic imbalances and normal-cell contamination. In this case, recent studies 
in our laboratory have tested the INS-1 cells used for proper glucose-response (Riopel et 
al., 2013). 
1.2.1 The Exocrine and Endocrine Pancreas 
The exocrine components of the pancreas comprise most of the organ’s mass and work to 
produce and secrete a multitude of enzymes into the intestine, including proteases such as 
trypsin and chymotrypsin, pancreatic lipase, and amylase. This amalgamation of enzymes 
collectively works to aid in the digestion of macromolecules into more readily absorbable 
forms (Slack, 1995; Moore and Dalley, 1999). The endocrine component, constituting 
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only ~2% of pancreatic mass, but ~10% of pancreatic blood flow, is made up of 
functional units called the Islets of Langerhans (Jansson, 1994; Brunicardi et al., 1996). 
Islets are composed of five different cell types. This includes insulin-secreting β-cells, 
responsible for glucose uptake in body tissues, and glucagon-secreting α-cells that 
stimulate glycogen breakdown to provide peripheral tissue with energy (Slack, 1995; 
Moore and Dalley, 1999). Somatostatin-secreting δ-cells, pancreatic polypeptide-
secreting PP cells, and ghrelin-secreting ε-cells are present in considerably fewer 
numbers (Andralojc et al., 2009). β-cells are of particular importance in current research 
due to their regulatory role with respect to carbohydrate metabolism, specifically in 
diabetes, a disease that affects multiple organ systems and stems from impairments of 
insulin secretion and defects in insulin action.  
1.2.2 Pancreatic β-Cells 
The most numerous islet cells, comprising 60-80% of the endocrine pancreas, are β-cells, 
responsible for secreting the hormone insulin, to reduce blood glucose levels upon 
elevated blood glucose concentration, measured by the passage of glucose through 
GLUT2 receptors (McCulloch et al., 2011). Once elevated blood glucose levels are 
detected by β-cells, insulin secretory response occurs as a biphasic process (Rorsman et 
al., 2000; Straub and Sharp, 2002). Transient stimulation of insulin secretion from 
granules in the readily releasable pool (<5% of total granule number), induced by 
elevation of blood glucose concentration, is followed by gradually developed secondary 
stimulation, thought to be an energy-dependent, active process requiring physically 
translocating or chemically modifying secretory granules (Rorsman et al., 2000). Insulin 
is then able to stimulate anabolic processes, such as glucose uptake by cells of the body 
and conversion of glucose to glycogen in the liver (Moore and Dalley, 1999).  This effect 
is counterbalanced by α-cell-mediated glucagon release, stimulating glycogenolysis and 
gluconeogenesis. 
β-cells produce a variety of other hormones and exert effects on the pancreatic 
microenvironment besides insulin detection and secretion. Under high concentrations of 
glucose or other environmental stressors, it has been found that β-cells begin to produce 
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proinflammatory cytokines, caused by accumulation of molecules such as tumor necrosis 
factor (TNF) and lymphotoxin α, which are important contributing factors to suppression 
of β-cell function and subsequent apoptosis in type 1 diabetics (Kagi et al., 1999; Eizirik 
et al., 2009). Besides cytokine-mediated pancreatic dysfunction, it is widely reported that 
β-cells, due to their dependency on islet vasculature, are influenced by a variety of 
proangiogenic factors, such as angiopoietin-2, and antiangiogenic factors, such as 
thrombospondin-1. These molecules are found in the microenvironment, and are able to 
provide positive and negative control for islet vasculature development, maintenance, and 
reconstruction. VEGF-A is secreted by β-cells, and is found to play a critical, non-
redundant role in angiogenic switching, a process that is characterized by a change in the 
balance of proangiogenic and antiangiogenic factors that allows tumors to develop in size 
and metastatic poetential, and pancreatic β-cell carcinogenesis (Folkman, 2002; Inoue et 
al., 2002). By modulation of these signaling molecules, mature β-cells are able to interact 
with intra-islet endothelial cells that create a supportive environment that is conducive to 
their survival and function. For example, recruited endothelial cells are able to synthesize 
the basement membrane laminin chains α4 and α5 to upregulate insulin gene expression 
and β-cell proliferation by interacting with laminin receptors containing β1-integrin 
(Nikolova et al., 2006). Additionally, β-cell-secreted angiogenic factors are required to 
maintain endothelial cell morphology which, in turn, allows for maintenance of their own 
structure and morphology (Figure 1.1) (Lammert et al., 2003).  
1.3 The INS-1 Cell Line 
Insulin-secreting cell lines (INS-1 and INS-2) were established using cells isolated from 
an x-ray-induced rat transplantable insulinoma. This cell line is unique, compared to 
those previously used, in that it retains features characteristic of physiological β-cells 
including morphology, insulin biosynthesis, and secretion. Unfortunately, similar to the 
phenotype observed in the parent tumor in vivo, these cells have a limited capacity for 
glucose-stimulated insulin secretion and are unable to synthesize and store normal levels 
of insulin. Compared to hamster beta cell lines, derived from hamster islet cells by SV40, 
and β-TC lines, derived from transgenic mice, INS-1 cells are able to retain glucose 
responsiveness and insulin content with increasing passage numbers (Asfari et al., 1992).  
5 
 
  
Figure 1.1 Schematic of inter-islet relationship between endothelial cell and β-
cell.  
Endothelial cells promote β-cell proliferation, survival and function by secreting 
hepatocyte growth factors (HGF), thrombospondin-1 (TSP-1), laminins, collagens. 
β-cells promote endothelial cell proliferation, vessel sprouting and angiogenic 
processes by secreting insulin, vascular endothelial growth factor-A (VEGF-A), 
and angiopoietin-1 (Ang-1) (Cao and Wang, 2014). 
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Several daughter cell lines were derived from the INS-1 and INS-2 cell lines, including 
INS-1 832, INS-1 832/2, and INS-1 832/13. The INS-1 832 and INS-1 832/2 cell lines 
exhibit higher insulin content than their parental cell lines. Due to low levels or 
insensitivity to cAMP, a molecule required in maintaining primary β-cells in a glucose 
competent state, these cell lines demonstrate relatively poor or unresponsive glucose-
stimulated insulin secretion (Yang et al., 2004). INS-1 832/13 cells, used in this study, 
were found to be very sensitive to cAMP, as evidenced by a relatively enhanced level of 
insulin secretion compared to INS-1 832/2 cells following forskolin or 
isobutylmethylxanthine stimulation or decreased insulin secretion when treated with a 
protein kinase A (PKA) inhibitor (Yang et al., 2004). Furthermore, when the regulatory 
subunit of PKA was overexpressed in the 832/13 cells, insulin secretion and PKA activity 
were severely inhibited (Yang et al., 2004). The glucose effect on this cell line is 
potentiated by insulin secretory agents such as IBMX, GLP-1, free fatty acids and 
sulfonylurea tolbutamide, and inhibited by potassium channel openers, with responses 
similar to adult rodent β-cells (Hohmeier et al., 2000). Importantly, INS-1 832/13 cells 
express Glut2 receptors and uses glucokinase, as opposed to hexokinase, to 
phosphorylate intracellular glucose (Skelin et al., 2010). Finally, the INS-1 832/13 cell 
line is derived from an insulinoma, it has endogenous proangiogenic factor production to 
support tumor growth, though it lacks a microenvironment that would normally create a 
balance between positive and negative angiogenic signal regulation. For these reasons, 
despite some limitations, the following study made use of the INS-1 832/13 cell line, due 
to their physiological resemblance to normal adult β-cells, compared to other available 
cell lines. Thus, manipulation of this cell line allows for insight into the mechanism 
behind disease state resulting from impairment of β-cells. 
1.4 Diabetes Mellitus (DM) 
Diabetes mellitus, screened and diagnosed by standards based on the World Health 
Organization (WHO) and Canadian Diabetes Association (CDA) criteria, is defined as an 
illness of the endocrine pancreas characterized by hyperglycemia, insulin resistance, and 
relative insulin deficiency (CDA, 2008). It is estimated that in 2011, 347 million people 
around the world were diabetic and diabetes is on track to become the 7
th
 leading cause of 
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death worldwide by 2030 (WHO, 2009; Danaei et al., 2011). In 2009, it was estimated by 
the CDA that over 2.3 million Canadians were living with diabetes, with 6 million others 
at elevated risk. It has been reported that, in 2009, the strain of diabetes on the Canadian 
healthcare system was $12.2 billion annually, projected to rise to $16.9 billion by 2020 
(CDA, 2008; Gougeon et al., 2014). 
Diabetes mellitus can be broken down into three subtypes: type 1 diabetes (insulin-
dependent), type 2 diabetes (non-insulin dependent), and gestational diabetes (GDM) 
(WHO, 2009). In type 1 diabetes, which comprises ~10% of the total diabetic population, 
pancreatic β-cells are destroyed by an autoimmune attack, resulting in the inability to 
produce and secrete insulin. Onset of type 1 diabetes typically occurs in children and 
young adults and is treated by insulin injections to normalize blood glucose (American 
Diabetes Association, 2010; Florez, 2014). Type 2 diabetes, comprising ~90% of all 
diabetes, is believed to be caused by a combination of genetic factors, such as carrying 
TCF7L2 allele, and lifestyle factors, such as poor diet, lack of exercise, and obesity. Type 
2 diabetes’ onset generally occurs toward middle age and can be characterized by insulin 
resistance in body tissues (primarily muscle, adipose, and liver) and often deficiency in 
insulin production and secretion, due to decreased β-cell mass (American Diabetes 
Association, 2010; Florez, 2014). Type 2 diabetes is a multifactorial illness, contributed 
to by the accumulation of many genetic and physiological factors exacerbated by 
oxidative stress caused by elevated glucose. This can result in an increase of 
mitochondrial reactive oxygen species (ROS) production, nonenzymatic glycation of 
proteins, and glucose autoxidation. Additionally, a variety of transcription factors and 
signaling pathways have been known to be activated by hyperglycemia, including NfκB, 
p38 MAPK and JNK/SAPK activation, all known to be activated by hyperglycemia, 
ROS, and accumulation of inflammatory cytokines (Evans et al., 2002). The 
simultaneous and additive exacerbation of these pathways is thought to play a part in the 
development of type 2 diabetes. GDM occurs during pregnancy, diagnosed in women that 
had not previously exhibited elevated blood glucose levels, and often resolves following 
delivery. Women are normally screened for high levels of glucose in order to provide 
treatment and management of GDM, typically with dietary adjustment, exogenous fast-
acting insulin injection, or medications such as metformin and glyburide (McIntyre et al., 
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2014). Complications associated with diabetes include significantly increased risk of 
cardiovascular disease, diabetic retinopathy, diabetic neuropathy, and a slew of other 
comorbidities that result in a shortened lifespan with a lower quality of life (American 
Diabetes Association, 2010; Florez, 2014). 
Currently, administration of exogenous insulin is the primary treatment for type 1 
diabetes, and advanced cases of type 2 diabetes, but only mitigates the negative effects 
and, as such, is not considered a cure for the illness. Type 2 diabetics are typically 
managed with a variety of lifestyle and dietary changes, and pharmacological treatments 
including increasing insulin secretion and sensitivity, β-cell replication and survival 
(Turner et al., 1998; Knowler et al., 2002; Jos et al., 2005). An alternative to exogenous 
insulin has emerged recently, in the form of islet transplantation. The Edmonton protocol 
is a popular islet transplantation procedure that has allowed patients to remain insulin-
independent after approximately a year. It involves isolation of islets from several 
cadaveric donor pancreata, and infusion into a patient’s hepatic portal vein, supplemented 
by a regimen of immunosuppressants in order to avoid autoimmune-mediated rejection 
(Shapiro et al., 2000). Unfortunately, a variety of issues exist with this procedure, since it 
moves islets into the hypoxic environment of the hepatic portal vein and there is a 
scarcity of donor tissue (Ryan et al., 2002). 
As previously mentioned, pancreatic islets exhibit a high degree of vascularisation, which 
is important for their ability to quickly secrete insulin in response to changes in blood 
glucose and to effectively deliver insulin to peripheral tissues. It is known that the 
procedure of pancreatic islet isolation severs the connections between islet vasculature 
and systemic circulation. This renders transplanted islets avascular for several days 
following the procedure, with overall less islet vascularisation and lower oxygen tension, 
compared to native pancreatic islets, even once vascularization has completed (Brissova 
et al., 2014; Irving-Rodgers et al., 2014). This work examines the possibility of a cell-
based therapeutic approach to combat significant islet cell death due to ischemia and 
compensate for impaired vasculogenesis following transplantation by targeting the 
receptor tyrosine kinase (RTK), c-Kit, which has already been shown to play an 
important role in β-cell survival, migration, and function in vivo. c-Kit signaling as a cell-
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based therapy for enhancement of β-cell function has been previously demonstrated by 
transplantation of bone marrow-derived c-Kit-expressing cells that resulted in initation of 
islet regeneration in streptozotocin-treated non-obese diabetic/severe combined 
immunodefficient (NOD/SCID) mice (Hess et al., 2003). Since one of the main issues 
with islet transplantation, as opposed to a regiment of exogenous insulin delivery, is the 
limitations of islet donors, it is crucial to ensure maximum islet survival and function in 
the long term by improving post-transplant vasculogenic function (Brissova, 2008). Thus, 
applying similar protocols following islet transplantation in order to aid in β-cell survival 
and revascularization is potentially a viable course of treatment. 
1.5 c-Kit Receptor Tyrosine Kinase and Stem Cell Factor 
1.5.1 c-Kit Receptor Tyrosine Kinase 
c-Kit (CD-117), a class III receptor tyrosine kinase (RTK) structurally similar to the 
colony stimulating factor-1 receptor (CSF-1R) and the platelet-derived growth factor 
receptor (PDGFR), is encoded by the c-Kit proto-oncogene (Yarden et al., 1987). The c-
kit gene has been mapped to the dominant white spotting (W) locus on mouse 
chromosome 5 and human chromosome 4q11-q21 with two or four reported isoforms in 
mice and humans, respectively, as a result of alternative splicing. These isoforms are 
characterized by the presence or absence the tetrapeptide sequence, Gly-Asn-Asn-Lys 
(GNNK), in the extracellular domain and, in humans, the presence or absence of a serine 
residue in the interkinase region of the cytoplasmic domain (Geissler et al., 1988).  The c-
Kit isoform lacking the tetrapeptide sequence has been shown to induce stronger but 
transient signals and have a higher transforming ability, compared to its GNNK-included 
counterpart (Caruana et al., 1999; Voytyuk et al., 2003). 
c-Kit is a transmembrane protein containing an extracellular domain, a single 
transmembrane region, an inhibitory cytoplasmic juxtamembrane domain, and a split 
cytoplasmic kinase domain separated by a kinase insert segment (Figure 1.2) 
(Lennartsson and Ronnstrand, 2006). The extracellular region is composed of five 
immunoglobulin-like domains, the first three of which form a concave surface that serves  
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Figure 1.3 Schematic of c-Kit, a transmembrane receptor tyrosine kinase.  
The extracellular region is composed of five immunoglobulin-like domains, the first three 
of which form a concave surface serving as a ligand-binding site for stem cell factor (SCF). 
The fourth and fifth domains play a role in receptor dimerization. The intracellular region is 
composed of a juxtamembrane domain with an ATP-binding region and a 
phosphotransferase region, containing 9 identified phosphorylation sites, split by a 77 
amino acid kinase insert and a COOH tail (Ashman, 1999). 
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as a ligand binding site for Stem Cell Factor (SCF). The fourth and fifth domain, 
however, are thought to play a role in c-Kit dimerization (Lev et al., 1992; Blechman et 
al., 1995). Additionally, the fifth domain is thought to allow the c-Kit receptor to be 
cleaved by proteases to allow shedding from the membranes of hematopoietic, mast, and 
endothelial cells (Pandiella et al., 1992). The intracellular region of c-Kit is composed of 
a juxtamembrane domain with an ATP-binding region and a phosphotransferase region 
containing multiple autophosphorylation sites, split by a 77 amino acid kinase insert, and 
a COOH tail (Brannan et al., 1992; Linnekin, 1999).  
1.5.2 Stem Cell Factor 
SCF, c-Kit’s ligand, is a cytokine produced by keratinocytes, fibroblasts and endothelial 
cells as well as endocrine cells in either a soluble form or as a transmembrane protein 
after alternative splicing and proteolytic cleavage of 8 exons that, upon binding to c-Kit, 
is linked to growth and differentiation of melanocytes, hematopoietic, mast, germ, and 
pancreatic islet cells (Tajima et al., 1998; Li et al., 2006; Feng et al., 2012). It has been 
shown that several cancer cell lines are also able to produce low amounts of soluble SCF 
(Beck et al., 1995). SCF has been mapped to the Steel (Sl) locus on mouse chromosome 
10 and human chromosome 12q22-24, expressed as four or six isoforms in mice and 
humans, respectively, following alternative splicing (Martin et al., 1990; Zsebo et al., 
1990). Of these, two transcripts are mainly expressed, encoding membrane-bound SCF, 
that can be cleaved by the metalloproteinase MMP-9, to form a third soluble form, with 
an extracellular domain, transmembrane domain, and an intracellular region (Figure 1.3) 
(Anderson et al., 1990; Majumdar et al., 1994; Oriss et al., 2014). The first form of SCF 
is membrane-bound SCF248, a 45 kD glycoprotein, which can be cleaved by proteases at 
the sixth exon to produce soluble SCF165. The second isoform, SCF220, a 32 kD 
glycoprotein, lacks a sixth exon and thus remains bound to the membrane, however can 
be cleaved at a secondary cleavage site located, in mice, at the seventh exon to create a 
soluble form (Majumdar et al., 1994). Both the transmembrane and soluble forms of SCF 
have been found to be biologically active, but serve different functions in mediating the 
effects of c-Kit. For example, experiments performed with Sl/Sl
d
 mouse models that 
produce either only soluble SCF or only membrane-bound SCF, show that the 
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Figure 1.4 Schematic of the three forms of SCF primarily expressed in rodents.  
Two membrane-bound isoforms of SCF include SCF220 and SCF248, while SCF165 is soluble. 
SCF 248, a 45 kD glycoprotein can be cleaved at the sixth or seventh exon to form soluble 
SCF165. SCF220, a 32 kD glycoprotein, lacks a sixth exon, but can be cleaved at the seventh exon 
to create soluble SCF165. All forms of SCF are biologically active, however membrane-bound 
SCF is able to readily form dimers, and is responsible for persistent activation and a prolonged 
lifespan of c-Kit, whereas soluble SCF induces transient receptor activation and enhances c-Kit 
protein degradation (Ashman, 1999). 
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 membrane-bound form was able to partially recover from anemia, bone marrow 
hypocellularity, and runting, while the soluble form restored myeloid progenitor cell 
numbers (Kapur et al., 1998). It has been shown that membrane-bound SCF is able to 
form dimers, which are more biologically active than monomers (Kurosawa et al., 1996). 
Soluble SCF, however, has been shown to exist primarily in monomer form, where it is 
less potent in activating c-Kit. Evidence has shown that membrane-bound SCF is 
responsible for persistent activation and a prolonged lifespan of c-Kit, whereas soluble 
SCF induces transient receptor activation and enhances c-Kit protein degradation (Philo 
et al., 1996; Lemmon et al., 1997). 
1.5.3 c-Kit Receptor Tyrosine Kinase & Signaling Pathways 
c-Kit signaling begins as SCF forms homodimers and binds to the three extracellular 
immunoglobulin domains located on the c-Kit receptor. This process is stimulated by 
binding of the SCF dimer to two receptor monomers (Lemmon et al., 1997). c-Kit 
dimerization results in subsequent autophosphorylation of tyrosine residues, located 
primarily outside the kinase domain (Blume-Jensen et al., 1995; Lemmon et al., 1997). 
These phosphorylated tyrosine residues are then able to mediate binding and activation of 
signaling molecules within the cytoplasm that have Src homology 2 (SH2) or phosphor-
tyrosine binding (PTB) domains. In the c-Kit RTK, a total of nine potential 
phosphorylation residues have been identified (in rodents: Tyr566, 568, 701, 719, 728, 
745, 821, 898, and 934) (Figure 1.2) that serve as high-affinity binding sites for signal 
transduction molecules (Ronnstrand, 2004). Phosphorylation of these sites can yield 
activation of several major intracellular signaling pathways. Phosphorylation at Y719 
results in activation of the phosphatidyl-inositol-3 kinase (PI3K) pathway, which 
promotes cell survival, migration and proliferation (Young et al., 2006). Phosphorylation 
at Y701 and Y934 causes an association with the adapter protein Grb2, which links to the 
Ras/Erk pathway through association with SHP-2. This complex is then able to begin a 
signaling cascade, which results in the activation of mitogen-activated protein kinase 
(MAPK), a signaling molecule that can act on transcription factors to modulate gene 
expression, and is essential for cell survival and proliferation (Ronnstrand, 2004; Sun et 
al., 2007).  
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Phosphorylation at Y566, 568, and 934 results in activation of the v-src avian sarcoma 
(Src) pathway, which plays a role in adhesion, chemotaxis, survival, proliferation and 
protein trafficking (Price et al., 1997; Thommes et al., 1999; Wollberg et al., 2003). 
Furthermore, it has been shown that murine myeloid 32D cells and mouse models with 
mutated Y566 and Y568 sites resulted in not only inhibition of the Src pathway, but also 
reduced activation of the PI3K, Ras/Erk and Janus kinase/Signal Transducers and 
Activators of Transcription (JAK/STAT) pathways (Bondzi et al., 2000; Lennartsson et 
al., 2005). These effects were reversed following restoration of Y566 and Y568 to these 
mutant models, suggesting that Src, in part, converges with them (Hong et al., 2004; 
Ronnstrand, 2004). Phosphorylation at Y728 results in the recruitment of phospholipase 
C-γ (PLC-γ), which exists as two isoforms: PLC-γ1 and PLC-γ2. The former is 
ubiquitously expressed, while the latter is mainly expressed in the hematopoietic system. 
This molecule is responsible for controlling calcium release in cells, a process vital to a 
variety of cellular functions (Gommerman et al., 2000). 
c-Kit activation is negatively regulated by several cellular mechanisms. Protein kinase C 
(PKC) are a family of serine/threonine kinases that serve as regulators for c-Kit and other 
RTKs, activated by increases in intracellular levels of diacylglycerol (DAG) (Blume-
Jensen et al., 1994). In this case, DAG is accumulated by c-Kit-mediated PI3K activation. 
This, in turn, stimulates PKC to phosphorylate S741 and S746, serine residues located in 
the kinase region of c-Kit that serve to attenuate its downstream signaling capabilities 
(Blume-Jensen et al., 1995). Additionally, suppressors of cytokine signaling (SOCS) are 
another family of proteins that work to suppress RTKs such as c-Kit. SOCS-1 has been 
found to be induced by SCF stimulation of mast cells, binding to c-Kit by its SH2 domain 
(Sepulveda et al., 1999; Yasukawa et al., 2000). SOCS-1, specifically, has been shown to 
suppress c-Kit-stimulated mitogenesis, but not interfere with survival signals by 
occupying Grb2 adaptor proteins via their SH3 domains (Sepulveda et al., 1999; Rottapel 
et al., 2002). 
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1.5.4 Role of SCF/c-Kit in Islet Biology 
Research, performed both in our lab and others, has demonstrated the significance of 
SCF/c-Kit interactions in the development and function of the islets of Langerhans, 
specifically in regard to β-cell proliferation, maturation and survival (Yashpal et al., 
2004; Li et al., 2007; Rachdi et al., 2001; Oberg-Welsh et al., 1994; LeBras et al., 1998; 
Oberg-Welsh and Welsh, 1996). c-Kit mRNA is found at detectable levels by embryonic 
day 13 in the rat pancreatic epithelial cells (Oberg-Welsh et al., 1994; LeBras et al., 
1998), as well as in fetal and adult rat islets, but not in acinar cells (Rachdi et al., 2001; 
Oberg -Welsh et al., 1994; LeBras et al., 1998; Oberg-Welsh and Welsh, 1996). Previous 
studies performed in our lab have demonstrated that c-Kit-expressing human and rat fetal 
pancreatic ductal epithelial cells exhibit high proliferation and SCF expression (Yashpal 
et al., 2004; Li et al., 2006; Li et al., 2007). Additionally, it was found that ductal cells of 
the ligated rat pancreas and islets of streptozotocin-induced diabetic rats had c-Kit 
expression, suggesting that c-Kit may play a role in β-cell regeneration (Peters et al., 
2005; Tiemann et al., 2007). In vitro experiments with cultured fetal rat islets treated with 
SCF showed a significant increase in insulin and DNA content (Oberg-Welsh and Welsh, 
1996). INS-1 cells treated with SCF were found to have an increased proliferative 
capacity (Rachdi et al., 2001). In contrast, siRNA-mediated c-Kit knockdown resulted in 
reduced islet cell differentiation, associated with a decrease in PDX-1 and insulin mRNA 
and protein levels, decreased cell proliferation, and increased cell death (Li et al., 2007). 
Taken together, these studies suggest that there is a profound correlation between c-Kit 
function and β-cell development and function.  
Experiments at the W locus of laboratory mice have demonstrated pleiotropic effects 
upon embryonic development and adult hematopoiesis, with most homozygotic mutations 
resulting in extensive white-spotting, sterility, and severe anemia resulting in perinatal 
mortality (Geissler et al., 1999). To obtain definitive information on c-Kit function in the 
β-cell in vivo, our lab used mice with a semi-dominant c-Kit mutation (c-KitWv/+), which 
expresses a non-functional c-Kit receptor with a less severe phenotype than c-Kit
Wv/Wv
 
mice. It has been shown that these mice developed a significant increase in blood glucose 
levels by 8 and 16 weeks, lowered insulin levels following glucose stimulation, and islets 
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with impaired insulin secretion in response to high glucose. These findings were further 
supported by decreases in β-cell mass and insulin content (Krishnamurthy et al., 2007). 
These effects were thought to be largely mediated by PI3K and its downstream signaling 
molecules, which was confirmed when c-Kit
Wv/+
 mice had downregulation of the Fas 
pathway by an lpr mutation, or inhibition of Gsk3β by 1-azakenpaullone injection, which 
resulted in the reversal of the adverse effects in c-Kit
Wv/+ 
mice (Feng et al., 2012A; Feng 
et al., 2013). Since this is a global mutation affecting every cell in the c-Kit
Wv/+ 
mice and 
does not reveal whether c-Kit has a primary or secondary role in β-cell function, our lab 
generated a novel transgenic mouse with β-cell specific c-Kit overexpression (c-KitβTg). 
This overexpression not only leads to improved β-cell function, with an increase in Pdx1 
and MafA transcription factor expression in normal and high fat diet-induced diabetic 
mice, but also prevents the early onset of diabetes observed in c-Kit
Wv/+ 
mice after cross-
breeding (Feng et al., 2012B). Interestingly, we noticed changes in -cell HIF-1 and 
VEGF-A expression as well as an alteration of islet capillary mass in c-Kit
Wv/+ 
mutant 
and c-KitTg mice. Taken together, these in vitro and in vivo studies suggest that the 
interactions between SCF and c-Kit may play a role in normal vascularization of the islet 
through an induction of VEGF-A expression in the -cell.  
1.6 Islet Microvasculature and Vascular Endothelial Growth 
Factor 
1.6.1 Islet Microvasculature 
As mentioned previously, the pancreas is a dual organ, consisting of both endocrine and 
exocrine tissues. However, there is an asymmetry in the distribution of blood vessels 
amongst its two integrated components. While the endocrine tissue comprises ~2% of the 
volume of a mature pancreas, the islets of Langerhans scattered throughout the exocrine 
pancreas receive ~10% of the organ’s total bloodflow (Jansson and Hellerstrom, 1983). 
Blood is supplied to the pancreas by the celiac and superior mesenteric arteries, and 
drains into the portal vein (Bonner-Weir and Orci, 1982; Murakami et al., 1992). 
Developmental studies based on embryonic growth have determined that there is separate 
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vascularisation, ductal drainage, and varied composition of islets. This demonstrates that 
the head of the pancreas, composed of pancreatic polypeptide-rich and glucagon-poor 
islets, is supplied by the superior mesenteric artery, while the glucagon-rich pancreatic 
polypeptide-poor body and tail are supplied by the celiac via the splenic artery (Ohtani, 
1983; Ohtani et al., 1986). Interlobular arteries and veins run parallel to major ducts in 
the several lobuli that compose the pancreas, and all pancreatic veins empty their 
hormone-infused blood into the portal vein (Bockman, 1992). Lymph vessels in the 
pancreas are generally not prominent under normal conditions, but a capacity for 
drainage of fluids becomes evident during pancreatitis (O’Morchoe, 1997). 
Studies in pancreatic vascular flow utilizing ink- or dye-infused whole mounts or 
scanning electron microscopy of corrosion casts have determined that islets nest in a 
dense glomerular-like capillary network of arterioles such that no endocrine cell is more 
than a single cell away from arterial blood supply (Bonner-Weir, 1988). Endocrine 
capillaries are highly permeable, comparable to those of the small intestine, due to 
possessing relatively high levels of fenestration, reportedly 10 times that of their exocrine 
counterparts. Upon morphological analysis, it has been observed that endocrine 
capillaries also tend to have a greater diameter than those found in the exocrine pancreas 
(Henderson and Moss, 1985; Hart and Pino, 1986). The great density, size, and surface 
area of the endocrine capillary network highlights the importance of highly sensitive, 
thorough vascularisation that is essential to proper islet function. In the pancreas, it is 
thought that vasulature is regulated primarily by vascular endothelial growth factor-A 
(VEGF-A) binding to either vascular endothelial growth factor receptors 1 and 2 
(VEGFR-1 and VEGFR-2) (Lammert et al., 2003). 
1.6.2 VEGF and VEGFR 
Vascular endothelial growth factor (VEGF) is a family of signaling proteins that consists 
of seven members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and 
PIGF (Ortega et al., 1999; Carvalho et al., 2007). The monomeric form of these proteins 
have a common homology domain composed of a cystine knot motif, with eight cystine 
residues involved in inter- and intramolecular disulfide bonds at one end of a four-
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stranded β-sheet, allowing them to dimerize in an antiparallel side-by-side orientation 
(Neufeld et al., 1999; Ortega et al., 1999). 
VEGF-A, the primary vascular growth factor found in pancreatic β-cells, lung, kidney, 
heart, and adrenal gland, has been shown to exist in seven homodimeric isoforms with 
monomers consisting of 120, 144, 147, 164, 182, 188, or 205 amino acids in rodents, with 
majority appearing in the pancreas as the 120, 164, or 188 amino acid forms (Figure 1.4) 
(Qaum et al., 2001; Vasir et al., 2001). There is a single VEGF-A gene coding for eight 
exons (Poltorak et al., 1997; Neufeld et al., 1999), with conservation of exons 1 to 5 and 
8 in all isoforms, except VEGF-A
147
, and alternative splicing of heparin-binding domain-
encoding exons 6 and 7 (Ruhrberg et al., 2002; Hoeben et al., 2004). VEGF-A
188
, which 
contains exon 6, is bound tightly to cell surface heparin-containing proteoglycans in the 
extracellular matrix, VEGF-A
164
 contains exon 7 is moderately diffusible, and VEGF-
A
120
, lacking exon 6 or 7, is highly diffusible (Ortega et al., 1999). Upon dimerization, 
VEGF proteins are able to bind to three types of RTKs, composed of a 750 amino-acid-
residue extracellular domain organized into seven immunoglobulin-like domains, a 
transmembrane region, a juxtamembrane domain, a split tyrosine-kinase domain 
interrupted by a 70 amino acid kinase insert, and a C-terminal tail, named: the fms-like 
tyrosine kinase Flt-1 (VEGFR-1/Flt1), the kinase domain region (VEGFR-2/Flk-1), and 
Flt4 (VEGFR-3) (Christinger et al., 2004). In the context of pancreatic islets, VEGFR-1 
and VEGFR-2 are expressed almost exclusively on endothelial cells, while functional 
endocrine cells, such as β-cells, lack VEGFR expression (Figure 1.4) (Ortega et al., 
1999). VEGFR-2 is the primary receptor responsible for mediating mitosis and migration 
of endothelial cells to promote angiogenesis, vasculogenesis, and increased vascular 
permeability, by stimulating endothelial production of platelet-activating factor (PAF) 
(McMahon, 2000; Hudry-Clergeon et al., 2005). VEGFR-1, containing ligand-binding 
site Ig domain-2, exhibits much weaker kinase activity, and is found to have a greater 
affinity for VEGF-A, compared to VEGFR-2, containing Ig domain-3 to determine 
ligand-binding specificity, suggesting that it is responsible for negatively modulating 
pathological vascularisation by competing with VEGFR-2 for substrate (Davis-Smyth et 
al., 1996; Shibuya, 2006). However, it has been found that VEGFR-1 may serve a role in 
cell migration, chemotaxis, and a minor role in angiogenesis and vasculogenesis (Barleon  
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Figure 1.5 Schematic of three isoforms of VEGF-A and two VEGF receptors (VEGFR) 
predominantly expressed in rodent pancreas.  
The single Vegf-A gene encodes all three isoforms, produced by β-cells, all of which express 
exons 1 to 5 and 8. VEGF-A
188
 contains exon 6 and is bound tightly to cell surface heparin-
containing proteoglycans in the extracellular matrix. VEGF-A
164 
contains exon 7 and is 
moderately diffusable. VEGF-A
120 
lacks exon 6 and 7 and is highly diffusable. VEGF-A can 
bind to VEGFR-1 and VEGFR-2 in heterodimeric and homodimeric forms, expressed on 
endothelial cells in the pancreas (Hoeben et al., 2004).
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et al., 1996; Tchaikovski et al., 2008). The presence of VEGFR-3 in the body is limited to 
lymphatic endothelial cells where activation results in their mitosis, migration, 
differentiation, and survival (Achen et al., 1998). 
1.6.3 VEGF Signaling 
Of the two receptors, VEGFR-1 and VEGFR-2, available in the pancreas for binding by 
VEGF-A dimers, VEGFR-2 is responsible for most kinase activity, while VEGFR-1 
serves primarily as a negative regulator due to a repressor sequence in the VEGFR-1 
juxtamembrane domain. VEGFR-2 activation, however, can lead to autophosphorylation 
of a total of six identified tyrosine residues (Y949, Y994, Y1052, Y1057, Y1173, Y1212) 
that can recruit an array of important signaling molecules (Olsson et al., 2006). 
Phosphorylation of Y1173, a kinase domain residue, creates a binding site for the SH2 
domain of PLCγ, which mediates activation of PKC, resulting in generation of 
intracellular calcium, and the mitogen-activated protein kinase (MAPK)/extracellular 
signal-regulated kinase 1/2 (Erk1/2) pathway, increasing proliferative capacity of 
endothelial cells (Ito et al., 1998; Takahashi et al., 2001). Additionally, phosphorylated 
Y1173 creates a binding site for the adaptor molecule, Shb, in order to activate the 
PI3K/Akt pathway (Sakurai et al., 2005). Active Akt is able to regulate nitric oxide (NO) 
production by phosphorylation of endothelial NO synthase (eNOS), allowing for 
modulation of vascular permeability (Parenti et al., 1998; Bates and Harper, 2002). 
Phosphorylation of Y949 creates a binding site for VEGFR-associated protein (VRAP), 
shown to be important in regulating endothelial cell migration (Wu et al., 2000; 
Grunewald et al., 2010). Phosphorylation of Y1212 results in activation of the p38MAPK 
pathway, resulting in modulation of vascular permeability, and activation of HSP27, 
responsible for actin remodeling and cell migration (Holmes et al., 2007). Together, these 
effects allow for angiogenesis and vasculogenesis in tissue with increased VEGFR-2 
activation.  
Several avenues of research have already demonstrated the importance of VEGF 
signaling within the context of the pancreas. One study showed that Pdx-1 promoter-
dependent overexpression of VEGF-A
164
 led to hypervascularization of the pancreas and 
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islet hyperplasia, as well as expression of insulin in cells of the posterior stomach 
epithelium (Lammert, 2001). RIP-Cre control of Vegf excision from the genome led to 
reduced islet endothelial cells and glucose-stimulated insulin secretion (Watada, 2010). 
Another study has linked VEGF-A expression to formation of endothelial cell 
fenestrations, an important feature in islet vascular structures (Brissova, 2006). 
Developmental studies have shown that mesoderm-derived signals from embryonic blood 
vessels are instrumental in supporting pancreas development, preceding the 
differentiation of endocrine cells (Lammert, 2001). This observation was further 
confirmed in murine homozygous knockouts of VEGFR-2, where expression of Pdx-1 in 
the dorsal pancreas remained unchanged, compared to controls, but the bud never 
emerged, Pdx-1
+
 cells were decreased, and Ptf1a expression was lost (Yoshitomi, 2004). 
The ventral pancreas in these knockout mice was able to bud normally, but had severe 
defects in vasculature, further establishing the essential role that VEGF-A/VEGFR-2 
signaling plays in the formation of vascular and pancreatic formation at the embryonic 
stage. 
1.6.4 Transcription Factor HIF-1α 
The primary stimulus for angiogenesis and vasculogenesis is hypoxia (Lin et al., 2004). 
The transcription factor monomer, hypoxia-inducible factor 1α (HIF-1α), stable under 
hypoxic conditions, is able to bind to the constitutively expressed hypoxia-inducible 
factor 1β (HIF-1β) in the cytosol to form an active dimeric form, HIF-1 (Salceda and 
Caro, 1997; Richard et al., 1999). VEGF-A expression is closely related to HIF-1 
formation and, thus, HIF-1α production, since it has been shown to be induced when cells 
are subject to hypoxic or hypoglycemic conditions (Kamiyama et al., 2005; Jeon et al., 
2007). HIF-1 is a heterodimer whose monomeric parts are both basic-helix-loop-helix 
per-aryl hydrocarbon receptor nuclear translocator-sim proteins (Forsythe et al., 1996; 
Ryan et al., 1998). HIF-1α prolyl hydroxylases (HPH)/prolyl hydroxylase domain 
proteins (PHD) 1-3 hydroxylate proline 402 and proline 564, while factor inhibiting HIF-
1 (FIH-1) is able to hydroxylate asparagine 803 (Semenza, 2001; Semenza, 2007). These 
mechanisms are thought to be limited by the cellular presence of O2, allowing for 
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regulation of HIF-1 function.  Following proline hydroxylation, HIF-1α is able to interact 
with von Hippel-Lindau tumor-suppressor protein (VHL), ubiquitinilating it and marking 
it for proteosomal degradation. Asparagine hydroxylation prevents HIF-1α interaction 
with co-activators CBP and p300, which also serves to inhibit HIF-1α function (Semenza, 
2004). The functional HIF-1 imposes its effects on VEGF-A transcript production by 
acting in conjuction with coactivator proteins CBP, p300, SRC-1, and TIF-2 to bind to 
Hypoxia Regulated/Responsive Element/Enhancer sequences in the 5’ and 3’ regions of 
the VEGF-A gene (Ferrara and Davis-Smyth, 1997; Ryan et al., 1998; Dachs and Tozer, 
2000; Tsuzuki et al., 2000; Semenza, 2001). In this way, HIF-1 is able to efficiently 
modulate vasculogenesis and angiogenesis in mammalian tissue. 
1.6.5 Relationship between c-Kit/SCF and VEGF-A 
Multiple studies have indicated a possible connection between SCF/c-Kit signaling and 
VEGF-A production and secretion in the pancreas. SCF treatment of an H526 small cell 
lung cancer cell line showed increased VEGF expression. This effect was shown to be at 
least partially dependent on HIF-1 formation and was inhibited by Ly294002 treatment (a 
PI3K inhibitor) (Litz and Krystal, 2006). Mammary tumor cell lines transfected with 
antisense SCF DNA showed tumors with significantly decreased numbers of mast cells 
and decreased microvascular density (Zhang et al., 2000). In adipose tissue-derived stem 
cells, VEGFR-2 antagonism and MAPK inhibition resulted in decreased c-Kit expression 
(Bai, 2007). Furthermore, c-Kit and VEGF were found to co-localize in human metastatic 
melanoma samples (Heissig, 2003). A model of pancreatic islet cancer treated by SU5416 
(VEGFR inhibitor) and Gleevec (RTK inhibitor) showed repression of lage-stage tumors 
(Bergers, 2003). Gleevec treatment, inhibiting c-Kit and PDGFR, showed significant 
reduction of VEGF expression in neuroblastoma cell lines, leading to decreased tumor 
volume following injection in SCID mice (Beppu, 2004). Another study found that mast 
cell infiltration and activation in tumors was mediated largely by tumor-derived SCF, 
indicating that even low concentrations of SCF were able to induce chemotactic 
migration of mast cells (Huang et al., 2008). It was reported that in hypoxic MCF-7 
breast cancer cells, SCF expression was increased at both the mRNA and protein levels, 
and that HIF-1α knockout by RNA interference, SCF expression and c-Kit 
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phosphorylation were both significantly reduced (Han et al., 2008). Studies on VEGF-A 
have shown a relationship with metalloproteinase MMP-9, a protein that is responsible 
for cleavage of membrane-bound SCF as well as neutrophil-mediated activation of 
VEGF-A (Christoffersson et al., 2012). Taken together, these studies indicate a definite 
link between c-Kit activation and the effects of VEGF-A on mammalian tissues in both in 
vitro and in vivo models. However, the role of c-Kit-induced VEGF-A production from 
β-cells in islet vascularization and the associated molecular mechanisms are largely 
unknown. The purpose of my thesis is to dissect the role of SCF/c-Kit interactions in 
regulating β-cell VEGF-A production and associated signaling pathways. 
1.7 Objectives, Hypothesis and Specific Questions 
1.7.1 Objective 
To investigate the functional role of c-Kit in the regulation of β-cell VEGF-A production 
and the associated intracellular signaling pathway in an in vitro model. 
1.7.2 Hypothesis 
An increase in c-Kit activation will stimulate VEGF-A production in β-cells via the 
PI3K/Akt/mTOR pathway. 
1.7.3 Specific Questions 
1. Can VEGF-A production and secretion be stimulated by exogenous activation of 
c-Kit in vitro? 
2. Will siRNA-mediated knockdown of c-Kit attenuate VEGF-A production and 
secretion in vitro? 
3. If c-Kit regulates VEGF-A production in β-cells, which intracellular signaling 
molecules are involved? 
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Chapter 2  
2 Research Design and Methods 
2.1 Cell Culture and Treatments 
INS-1 (832/13) cells (a gift from Dr. Christopher Newgard, Duke University Medical 
Center, USA)  were thawed in a 37
o
C waterbath and transferred to a 25 cm
2
 tissue culture 
flask (Corning/VWR; Toronto, ON, Canada) cultured with 3-4 mL of RPMI-1640 
medium with L-glutamine and 11.1 mmol/L glucose containing 10% fetal bovine serum 
(FBS; Invitrogen; Burlington, ON, Canada), 10 mmol/L HEPES (Sigma; Oakville, ON, 
Canada), 1 mmol/L sodium pyruvate (Invitrogen) and 50 μmol/L β-mercaptoethanol 
(Sigma) (Jensen et al., 2001; Pederson et al., 2007) . Cells were cultured and expanded at 
37
o
C in an incubator under humidified conditions with 95% air and 5% CO2 to near 
(~80%) confluence. Cells were subcultured onto 12-well plates (Corning/VWR) at a 
density of 8x10
4
 cells/well and allowed to grow to confluence. Prior to SCF-treatment 
and inhibitory experiments, subcultured cells were starved overnight in serum-free 1% 
bovine serum albumin (BSA; Sigma) RPMI-1640 medium in order to eliminate the 
presence of medium-based growth factors. All experiments are performed at 5-10 passage 
of the culture. 
2.1.1 Dose and Time of SCF Treatment 
After overnight incubation in serum-free RPMI-1640 1% BSA medium, INS-1 cells were 
treated with human recombinant SCF (SCF; ID Labs; London, ON, Canada), where the 
extracellular domain of human SCF is fused to the N-terminus of the Fc region of a 
mutant human IgG1, at dosages of: 10, 20, 30, 50 and 100 ng/mL, or were used as a 
control, treated with an SCF vehicle (10 mM acetic acid), for 24 hours. To establish an 
optimal treatment time, INS-1 cells were treated with SCF with the optimal dose of SCF 
(50 ng/mL) based on the information from the dosage experiments compared to the SCF 
vehicle (10 mM acetic acid), and cultured for 1, 6, or 24 hours. At each dose and time-
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point, cell culture medium was collected and stored at -20
o
C for quantification of VEGF-
A release using a VEGF-A ELISA.  
2.1.2 SCF Treatment of INS-1 Cells 
Based on the results from the dose and time study, the dosage of 50 ng/ml and 24 h of 
SCF treatment was chosen.  Following subculture of INS-1 cells onto 12-well plates, 
cells were allowed to grow to ~80% confluence overnight in 10% FBS RPMI-1640 
medium. Cell media was then replaced with serum-free 1% BSA RPMI-1640 medium to 
starve the cells overnight. Following overnight starving, media was replaced with 600 μL 
of fresh 1% BSA RPMI-1640 medium per well, and cells were treated with either SCF at 
a concentration of 50 ng/mL or an SCF vehicle (10 mM acetic acid) for 24 hours. At the 
end of experiments, INS-1 cells were harvested and washed with phosphate buffered 
saline (PBS) and immediately processed for either RNA or protein extraction, or cells 
were fixed and embedded in paraffin for immunofluorescence staining analyses. Samples 
from at least three to four cell passages per experimental group were collected. 
2.1.3 PI3K or mTOR Inhibitory Study in SCF-treated INS-1 Cells 
INS-1 cells were prepared and cultured as previously described, and treated with one of 
two inhibitors either with or without the presence of SCF. For the PI3K inhibitor study, 
INS-1 cells were incubated with Lys294002 (Promega Madison; Madison, WI, USA) at 
concentrations of 1, 10, or 100 μmol/L, or untreated with serum-free medium serving as a 
control, supplemented with either SCF at a concentration of 50 ng/mL or an SCF vehicle 
(10 mM acetic acid), for a period of 24 hours. Lys294002 is able to inhibit PI3K 
activation by competing with ATP for the active site of catalytic subunit p110 (Walker et 
al., 2000). For the mTOR inhibitor study, INS-1 cells were treated with rapamycin (LC 
Laboratories; Woburn, MA, USA) at concentrations of 5, 20, or 100 nmol/L or untreated 
with serum-free medium, serving as a control, for 30 minutes prior to the addition of 
either SCF at a concentration of 50 ng/mL or an SCF vehicle (10 mM acetic acid) for a 
period of 24 hours. Rapamycin is able to impose its effects on mTORC1 formation by 
binding to its immunophilin, FK binding protein (FKBP12), which then interacts with 
30 
 
mTOR to inhibit its function (Dutcher, 2004). In both cases, following the treatment 
period, 500 μL of cell media was collected and stored at -20oC for analysis of VEGF 
release by ELISA. 
2.1.4 Transfection of INS-1 Cells with c-Kit siRNA 
INS-1 cells were subcultured onto 12-well plates (Corning/VWR) at a density of 8x10
4
 
cells/well and allowed to grow near confluence. Prepared c-Kit (r) siRNA (sc-63363) and 
control siRNA (sc-36869, proprietary sequence) (Santa Cruz Biotechnology Inc; Dallas, 
TX, USA) transfection mixture per well of 12-well plate: (a) 3.6 μL of siRNA duplex was 
added into 60 μL of siRNA Transfection Medium (sc-36868), and (b) 3.6 μL of siRNA 
Transfection Reagent (sc-29528) was added into 14.5 μL of siRNA Transfection 
Medium. Each mixture was incubated for 5 minutes at room temperature, the siRNA 
duplex solution (a) was added directly to the dilute Transfection Reagent (b), mixed 
gently, and incubated for 25 minutes at room temperature. As per manufacturer 
instructions, 600 μL of fresh 10% FBS DMEM/F12 medium was added to each well 
followed by either c-Kit siRNA or control siRNA transfection mixtures. Serum-free 
media was not used in accordance to manufacturer instructions, to preserve function and 
transfection efficiency that would otherwise be degraded in serum-free media. Cells were 
cultured for either 48 or 72 hours at 37
o
C in a tissue culture incubator. A pool of three 
sequences, recommended by the manufacturer to increase the knockdown effect by 
targeting three different potential binding sites, for rat c-Kit siRNA (Santa Cruz) were 
used: (1) 5ʹ-CCA UGU GGA UAA AGU UGA Att-3ʹ (sense), 5ʹ-UUC AAC UUU AUC 
CAC AUG Gtt-3ʹ (antisense); (2) 5ʹ-GAU GGU UCU UGC CUA CAA Att-3ʹ (sense), 5ʹ-
UUUGUA GGC AAG AAC CAU Ctt-3ʹ (antisense); (3) 5ʹ-GCA AGA AUA GAC UCG 
UAU Att-3ʹ (sense), 5ʹ-AUA ACG AGU CUA UUC UUG Ctt-3ʹ (antisense). Following 
experimental procedures, culture medium was collected and stored at -20
o
C for VEGF 
ELISA, or cells were harvested and prepared for qRT-PCR, western blot, or 
immunofluorescence staining. Samples from at least three to four cell passages per 
experimental group were collected. 
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2.2 VEGF-A ELISA 
VEGF-A release in treated INS-1 cell cultures was detected using a Rat VEGF Mini 
ELISA Development Kit (PeproTech Canada; Dollard Des Ormeaux, QC, Canada) 
according to manufacturer instructions. A total of 50 μg antigen-affinity purified 
polyclonal rabbit anti-rat VEGF capture antibody with D-mannitol was diluted in 0.5 mL 
of sterile water to a concentration of 100 μg/mL, then diluted in 1x PBS to a 
concentration of 0.5 μg/mL. 100 μL was added to coat each well of an ELISA microplate 
(Corning/VWR). The plate was sealed with manufacturer-provided sealing film, and 
incubated at room temperature overnight. Wells were aspirated and washed four times 
with 300 μL of wash buffer, containing 0.05% Tween-20 (Sigma) in 1x PBS, then the 
plate was inverted to remove residual buffer. 300 μL of blocking buffer containing 1% 
BSA (Sigma) in 1x PBS was added to each well and incubated for 1 hour at room 
temperature, followed by aspiration and four more washes, as described previously. The 
rat VEGF standard (PeproTech Canada), containing 1 μg of recombinant Rat VEGF, 2.2 
mg of BSA, and 11.0 mg of D-mannitol, was diluted into 1 mL of sterile water, and 
serially diluted in dilutent solution (0.05% Tween-20 [Sigma], 0.1% BSA [Sigma] in 1x 
PBS) into varying concentrations, ranging from 2 ng/mL to zero. 100 μL of standard or 
thawed treated INS-1 cell medium sample was added to each well in triplicate and 
incubated at room temperature for 2 hours. 50 μg of biotinylated antigen-affinity purified 
rabbit anti-rat VEGF detection antibody with 2.5 mg of D-mannitol (PeproTech Canada) 
was diluted in 0.5 mL of sterile water to a concentration of 100 μg/mL. The solution was 
diluted again in dilutent solution to a concentration of 0.5 μg/mL. 100 μL was added, per 
well, and incubated at room temperature for 2 hours. Wells were aspirated and washed 
four times, as described previously, and 100 μL of dilute Avidin-HRP conjugate 
(1:2000)(# A-7419; Sigma) was added, per well, and incubated for 30 minutes at room 
temperature. Wells were aspirated and washed four times, then 100 μL of ABTS Liquid 
Substrate Solution (# A3219; Sigma) was added to each well, and incubated at room 
temperature for colour development. Readings were taken with Multiskan spectrum 
spectrophotometer (Thermo Scientific; Vantaa, Finland) at 405 nm with wavelength 
correction set to 650 nm. Data are expressed as rat VEGF content in pg/mL. 
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2.3 mRNA Extraction and qRT-PCR Analysis 
To quantify relative gene expression levels of Hif-1α and Vegf-A in INS-1 cells following 
SCF [50 ng/mL] treatment or c-Kit (r) siRNA-mediated knockdown, mRNA was 
extracted from INS-1 cells cultured in 12-well culture plates (Fisher Scientific), 24 hours 
following SCF treatment, or 48 hours following c-Kit (r) siRNA-mediated knockdown, 
using a RNAqueous-4PCR kit (Invitrogen), according to manufacturer’s instructions 
(Wang et al., 2005; Krishnamurthy et al., 2007). To verify RNA quality, 1% agarose gel 
electrophoresis using ethidium bromide staining was performed for 18S and 28S 
ribosomal subunits, and images were captured under UV light. 
For each RT reaction, 2 μg of DNA-free RNA was heated at 60oC for 5 minutes, then 
kept at 4
o
C for 10 minutes. Two microtubes per sample containing RNA with 1 μL 
Oligo-(dT) primers, 2 μL of random hexamers/oligodeoxythymidine primers, and 
diethylpyrocarbonate (DEPC) water were prepared added for a total volume of 10.5 μL 
and an additional microtube containing no RNA was prepared, serving as a negative 
control. Microtubes were vortexed and centrifuged briefly, then placed in the T-gradient 
Biometra PCR thermal cycler (Montreal Biotech; Kirkland, QC, Canada) for 10 minutes 
at 72
o
C and 5 minutes at 4
o
C. Microtubes were removed from the PCR machine, and 
centrifuged briefly, then 8.5 μL of RT Master Mix (4.0 μL of 5x cDNA synthesis buffer, 
2.0 μL of DTT, 2.0 μL of 10 mM dNTPs, 0.5 μL of Rnasin) and was added to each tube 
and aspirated by pipette. A total of 0.8 μL of Superscript reverse transcriptase 
(Invitrogen) was added to each tube and left to sit for 1 minute. Microtubes were put into 
the PCR machine for 90 minutes at 42
o
C, 5 minutes at 94
o
C, and 60 minutes at 4
o
C. The 
tubes were put on ice and samples were collected, together, into a new tube with an equal 
amount of ddH2O. 
For qRT-PCR, 1 μL of sample cDNA was loaded into PCR tubes (Low Tube Strips; 
BioRad Laboratories) along with 5 μL of iQ SYBR Green Supermix (BioRad 
Laboratories), 3 μL of sterile H2O, 0.5 μL of appropriate forward primer, and 0.5 μL of 
appropriate reverse primer. Negative controls were loaded by replacing primer amounts 
with sterile H2O. PCR primers used included Vegf-A: F, 5ʹ-ACT GCC ATC CAA TCG 
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AGA CC-3ʹ and R, 5ʹ-GAG GTT TGA TCC GCA TAA TC-3ʹ (183 bp); Hif-1α: F, 5ʹ-
CTT GAA GAT GTC CCG TTG TA-3ʹ and R, 5ʹ-ACA TTG ACC ATA TCG CTG 
TCC-3ʹ (314 bp); c-Kit: F, 5ʹ-AGC AAG AGT TAA CGA TTC CGG AG-3ʹ and R, 5ʹ-
CCA GAA AGG TGT AAG TGC CTC CT-3ʹ (344 bp); and 18S: F, 5ʹ-GTA ACC CGT 
TGA ACC CCA TTC-3ʹ and R, 5ʹ-CCA TCC AAT CGG TAG TAG CG-3ʹ (151 bp). 
Tubes were analyzed in Chromo4 Real Time PCR (BioRad Laboratories), with at least 
three repeats per experimental group. Relative gene expression was determined by the 
arithmetic formula “2-ΔΔCt” (Wang et al., 2005; Feng et al., 2013). Data was normalized 
to the internal gene, 18S rRNA, while controls were established by a lack of amplified 
fragments following omission of reverse transcriptase, cDNA, or DNA polymerase. 
2.4 Protein Extraction and Western Blot Analysis 
At the end of culture, media was aspirated and INS-1 cells were washed with 1x PBS. 
Cells were then harvested and incubated in Nonidet-P40 lysis buffer (Nonidet-40, 
phenylmethylsulfonyl fluoride, sodium orthovanadate [Sigma]; complete inhibitor 
cocktail tablet [Roche]) for 30 minutes on ice. Cells were dispersed by sonicating to 
extract protein. Samples were centrifuged at 12,000 rpm for 20 minutes at 4
o
C, and 
supernatant was collected and frozen at -80
o
C for protein assay and western blot analysis. 
Protein concentration was measured by a protein assay with Bradford dye (BioRad 
Laboratories; Mississauga, ON, Canada), with standards prepared from bovine serum 
albumin (BSA) at concentrations of 0-0.5 mg/mL. 10 μL of each standard and 1 μL of 
each sample solution was loaded into micro titer plate wells in duplicate and mixed with 
the colorimetric dye. The plate was incubated at room temperature for 20 minutes, and 
readings were performed at 595 nm by a Multiskan spectrum spectrophotometer (Thermo 
Scientific). An equal amount (15 μg) of lysate protein samples, mixed with 6x sample 
buffer, from experimental groups and controls were separated by 5 (proteins greater than 
180 kDa), 7.5 (proteins 100-180 kDa) and 10% (proteins 20-100 kDa) sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)(Table 2.1). A constant voltage 
(40V) was applied to samples in order to migrate them through the stacking gel, after 
which voltage was increased (80V) as protein entered the resolving gel, until the dye 
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front reached the bottom. Protein was then transferred to a nitrocellulose membrane by 
electroelution with BioRad’s Transblot system using transfer buffer containing glycine 
(192 mM), Tris (25 mM) and methanol (20% v/v), and transferred at a constant current 
(250 mA) for 2.5 hours at 4
o
C on a stir-plate. To check protein transferring, a Ponceau S 
stain was used, followed by washing in Tris buffer-saline (TBS) containing 0.1% Tween-
20 (TBST). Membranes were incubated in 5% non-fat dry milk with TBST overnight at 
4
o
C to block non-specific binding. Membranes were then incubated with primary 
antibodies at the appropriate dilution (Table 2.1) for 2 hours at room temperature, and 
then incubated with goat anti-rabbit IgG or anti-mouse IgG horseradish peroxidise-
conjugated secondary antibody at appropriate dilution (Table 2.1) for 1 hour at room 
temperature.  Membranes were washed again in TBST after secondary antibody 
incubation and treated with enhanced chemiluminescent (ECL) reagents for 1 minute 
(Western Lightning® Plus–ECL, Perkin Elmer; Wellesley, MA, USA) to visualize 
protein. Images of immunoreactive bands were acquired using the Versadock 5000MP 
imaging system (Bio-Rad Laboratories Mississauga, ON, Canada) with Quantity One 
software (Bio-Rad Laboratories; Mississauga, ON, Canada). Densitometric quantification 
was performed using Image Lab 3.0 software (Bio-Rad Laboratories; Mississauga, ON, 
Canada) and normalized to either total protein or a loading control (GAPDH). 
2.5 Immunofluorescence Staining 
Following harvesting, cells were fixed in 4% paraformaldehyde (PFA) (Fisher Scientific 
Company; Ottawa, ON, Canada) overnight at 4
o
C, then embedded in 2% agarose gel, and 
processed into paraffin blocks (Wu et al., 2010), using an automated tissue processing 
and embedding machine (Shandon CitadelTM Tissue Processor, Citadel 1000, Thermo 
Electron Corporation; Waltham, MA, USA). Blocks were cut into sections using a 
microtome (Leica RM2245, Vashaw Scientific Inc.; Nocross, Atlanta, USA) onto glass 
slides (Fisher Scientific). 
Mounted samples were allowed to incubate at 37
o
C overnight, after which, they were 
deparaffinised by xylene for 10-minutes three times, and rehydrated with ethanol of 
varying concentrations, starting with 100% and concluding with 70%. Following 
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rehydration, slides were rinsed with deionized water, followed by 1x PBS washing. 
Nonspecific binding was blocked by applying 10% normal goat serum diluted in 1x PBS 
for 30 minutes at room temperature in a humidified container. Primary antibodies at 
appropriate dilutions, as listed in Table 2.2, were applied to sample sections and 
distributed evenly by application of a cover slip (Fisher Scientific). Sections were 
incubated overnight at 4
o
C in a humidified container. Following incubation with primary 
antibody, cover slips were removed and sections were rinsed with DI water, followed by 
1x PBS. Appropriate dilutions of secondary antibodies conjugated with either fluorescein 
isothiocyanate (FITC) or tetramethyl rhodamine isothiocyanate (TRITC)(Jackson 
Immunoresearch Laboratories; West Grove, PA, USA) (Table 2.2) were applied to 
sections and distributed evenly by application of a cover slip (Fisher Scientific). Sections 
were left to incubate for 1 hr at room temperature within a humidified container. 
Following incubation, cover slips were removed, and sections were rinsed with DI water, 
followed by 1x PBS. Cell nuclei were counterstained with 4’-6’-diamidino-2-phenylindol 
(DAPI) (Sigma) for 5 minutes at room temperature within a humidified container, then 
rinsed in 1x PBS. Cover slips were adhered to slides by fluorescence mounting medium 
(Dako; Burlington, ON, Canada). Negative controls were obtained by omission of 
primary and secondary antibodies. 
2.6 Morphometric Analyses 
Sections were viewed through a Leica DMIRE 2 fluorescence microscope (Leica 
Microsystems; Bannockburn, IL, USA) and images were taken with a digital camera 
(Retiga 1300, High-sensitivity IEEE 1394 FireWire
TM
 digital camera, QIMAGING; 
Burnaby, BC, Canada). Images were stored on a Windows computer, analyzed by 
ImagePro Plus imaging software (Media Cybernetics Inc; Rockville, MD, USA). The 
percentage of VEGF-A positive signaling in insulin-positive or insulin-negative cells, or 
insulin-positive with no VEGF-A staining was determined by cell counting. A minimum 
of 1000 cells per section per experimental group, with a minimum of three repeat 
experiments per group were counted. Co-localization of VEGF-A and insulin was 
determined as a percentage of total cells appearing in the section, characterized by DAPI 
counterstaining. 
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2.7 Statistical Analysis 
Data are expressed as means ± SD. Statistical significance was determined by either 
unpaired Student’s t-test or one-way ANOVA with the post-hoc Fisher’s least significant 
difference (LSD) test. Differences were considered statistically significant when p < 0.05. 
GraphPad Prism 6 (GraphPad Software; La Jolla, CA, USA) was used to conduct 
analyses. 
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Table 2.1 List of antibodies used for western blotting 
Primary Antibody Dilution Company; Location 
Molecular 
Weight 
Mouse anti-phosphorylated Akt (Ser 473) 1:2000 
Cell Signaling; 
Danvers, MA, USA 60 kDa 
Rabbit anti-Akt 1:3000 
Cell Signaling; 
Danvers, MA, USA 60 kDa 
Rabbit anti-phosphorylated GSK3β (Ser 9) 1:2000 
Cell Signaling; 
Danvers, MA, USA 46 kDa 
Rabbit anti-GSK3β 1:2000 
Cell Signaling; 
Danvers, MA, USA 46 kDa 
Rabbit anti-VEGF 1:2000 
Abcam; Cambridge, 
MA, USA 43 kDa 
Rabbit anti-β-catenin 1:1000 
Millipore; Billerica, 
CA, USA 92 kDa 
Rabbit anti-phosphorylated ErK1/2 
(Thr202/Tyr204) 1:3000 
Cell Signaling; 
Danvers, MA, USA 42, 44 kDa 
Rabbit anti-ErK1/2 1:5000 
Cell Signaling; 
Danvers, MA, USA 42, 44 kDa 
Rabbit anti-phosphorylated mTOR (Ser 2448) 1:1000 
Cell Signaling; 
Danvers, MA, USA 289 kDa 
Rabbit anti-mTOR 1:1000 
Cell Signaling; 
Danvers, MA, USA 289 kDa 
Rabbit anti-phosphorylated NFκBp65 (Ser536) 1:1000 
Cell Signaling; 
Danvers, MA, USA 65 kDa 
Rabbit anti-NFκBp65 1:1000 
Cell Signaling; 
Danvers, MA, USA 65 kDa 
Rabbit anti-phosphorylated P38 MAPK 
(Thy180/Tyr182) 1:1000 
Cell Signaling; 
Danvers, MA, USA 40 kDa 
Rabbit anti-P38 MAPK 1:1000 
Cell Signaling; 
Danvers, MA, USA 40 kDa 
Mouse anti-phosphorylated P70S6K (Thr389) 1:1000 
Cell Signaling; 
Danvers, MA, USA 65 kDa 
Rabbit anti-P70S6K 1:1000 
Cell Signaling; 
Danvers, MA, USA 70 kDa 
Rabbit anti-phosphorylated c-Kit (Tyr719) 1:1000 
Cell Signaling; 
Danvers, MA, USA 120  kDa 
Rabbit anti-c-Kit 1:500 
Abcam; Cambridge, 
MA, USA 107 kDa 
Rabbit anti-GAPDH 1:2000 
Santa Cruz 
Biotechnologies; Santa 
Cruz, CA, USA 37 kDa 
Secondary Antibody Dilution Company; Location  
HRP-conjugated Goat anti-mouse 1:2000 
Cell Signaling; 
Danvers, MA, USA  
HRP-conjugated Goat anti-rabbit 1:2000 
Cell Signaling; 
Danvers, MA, USA  
HRP-conjugated Goat anti-rat 1:2000 
Abcam; Cambridge, 
MA, USA  
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Table 2.2 List of antibodies used for immunofluorescence 
Primary Antibody Dilution Company; Location 
Guinea pig anti-insulin 1:50 Zymed Laboratories; San Francisco, CA, USA 
Mouse anti-VEGF 1:50 Santa Cruz Biotechnologies; Santa Cruz, CA, USA 
Rabbit anti-c-Kit 1:100 Abcam; Cambridge, MA, USA 
Secondary Antibody Dilution Company; Location 
Cy2/3 conj. Goat anti-
rabbit 1:50 Jackson Immunoresearch; West Grove, PA, USA 
Cy2/3 conj. Goat anti-
mouse 1:50 Jackson Immunoresearch; West Grove, PA, USA 
Cy3 conj. Goat anti-
guinea pig 1:50 Jackson Immunoresearch; West Grove, PA, USA 
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Chapter 3  
3 Results 
3.1 c-Kit and VEGF-A co-localization in INS-1 Cells 
To examine whether SCF/c-Kit interaction regulates VEGF-A production, co-expression 
of c-Kit and VEGF-A was analyzed. In order to clearly reveal the co-localization, we 
cultured INS-1 cells in serum-free medium containing 50 ng/mL SCF for 24 h. Cells 
were harvested and co-stained by double-immunofluorescence for c-Kit and VEGF-A. c-
Kit-positive signals were observed near the cell membrane, while VEGF-A was found 
primarily in the cytoplasm of INS-1 cells (Figure 3.1). 
3.2 Determining Sufficient Dosage and Time-points for VEGF-A 
Secretory Action in INS-1 cells 
To examine the ramifications of exogenous SCF-stimulated c-Kit activation on VEGF-A 
release in vitro, an optimal dosage and time at which c-Kit signaling exerts a quantifiable 
effect on secreted VEGF-A was established. SCF stimulation at concentrations of 10, 20, 
30, 50 and 100 ng/mL after 24 h in the INS-1 cell line (Baghestanian, 1997; Chung et al., 
2003; Ren et al., 2003; Feng et al., 2013) were first examined. VEGF-A accumulation in 
culture medium was assessed at each dose by a rat VEGF mini ELISA development kit, 
and showed no change in VEGF-A release when the cells treated with 10 and 20 ng/mL 
of SCF, but release began to increase at 30 ng/mL (p < 0.01, Figure 3.2). Cells treated 
with 50 ng/mL of SCF showed a further increase in VEGF-A release when compared to 
controls, reaching a plateau at 100 ng/mL (p < 0.001, Figure 3.2). This suggests that 50 
ng/mL at 24 hours was sufficient to elicit significant VEGF-A release response. To 
examine the time-dependent effect of SCF/c-Kit signaling on VEGF-A production, we 
treated INS-1 cells with SCF at a 50 ng/mL dosage for either 1, 6 or 24 hours followed by 
examination of VEGF-A release by ELISA. There were slight increases of VEGF-A 
levels in the culture medium at 1 hour, reaching statistical significance at 6 hours (p < 
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0.05, Figure 3.3), with greater significance at 24 hours of culture, when compared to 
time-matched controls (p < 0.01, Figure 3.3). 
3.3 Expression of Hif-1α and Vegf-A mRNA and VEGF-A 
Protein in INS-1 Cells Following SCF Treatment 
After establishing an optimal dose (50 ng/mL) at 24 h of SCF treatment in INS-1 cells, 
we examined changes in VEGF-A mRNA and protein levels. At the mRNA level, there 
was a significant increase in Hif-1  and Vegf-A mRNA levels 24 h following 50 ng/mL 
SCF treatment (p < 0.05, Figure 3.4A). Western blot analysis of VEGF-A protein levels 
in INS-1 cells showed a ~25% increase in VEGF-A protein levels in the SCF-treated 
group compared to controls, but did not reach statistical significance (Figure 3.4B). 
3.4 Increased numbers of VEGF-A and Insulin Double-positive 
cells following SCF Treatment 
Double immunofluorescence staining was performed to examine the co-expression 
pattern of VEGF-A
 
and insulin in INS-1 cells 24 h following 50 ng/mL SCF treatment 
(Figure 3.5A). Increased numbers of VEGF-A and insulin double positive cells in the 
SCF-treated group (89.2 ± 0.5%) were observed compared to the control group (85.0 ± 
1.5%) (p < 0.01, Figure 3.5B). However, the numbers of VEGF-A positive with no 
insulin staining (VEGF-A
+
 Insulin
-
) cells were reduced in SCF-treated cells (8.4 ± 0.5%) 
compared to controls (10.7 ± 0.9%) (p < 0.05, Figure 3.5C). Similarly, observation 
showed that insulin-positive cell populations without VEGF-A (VEGF-A
-
 Insulin
+
) were 
reduced in SCF-treated groups (2.5 ± 0.3%) compared to controls (4.3 ± 0.6%) (p < 0.01, 
Figure 3.5C). It is possible that, since this cell line has a high rate of proliferation, cells 
lacking insulin were in an early phase of growth, and had not yet acquired an insulin-
producing phenotype. 
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Figure 3.1 Co-localization of c-Kit and VEGF-A in INS-1cells.  
Double immunofluorescence staining for c-Kit (green) with VEGF-A (red) in INS-1 
cells cultured in serum-free medium plus 50 ng/mL SCF treatment for 24 h, shows co-
localization of c-Kit with VEGF-A. A representative image of live cell staining on the 
coverslips is shown and bottom panel shows magnified images each corresponding to 
the section within the square. Nuclei were stained with DAPI (blue); scale bar: 10 μm.  
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Figure 3.2 Comparison of VEGF-A secretion of INS-1 cells treated with varying 
concentrations of SCF for 24 h.  
INS-1 cells were cultured in 12-well plates and treated with varying concentrations of 
recombinant SCF [0, 10, 20, 30, 50, 100 ng/mL] for 24 hours to observe a dose-dependent 
VEGF-A secretory response. Culture medium was collected and analyzed for VEGF-A 
secretion. The Rat VEGF mini ELISA kit was used to quantify data. Data are expressed 
aspictograms per milliliter in means ± SD (n=4; ** p < 0.01, *** p < 0.001vs. 0 ng/mL group 
determined by one-way ANOVA with Fisher’s Least Significant Difference post-hoc test).  
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Figure 3.3 Comparison of VEGF-A accumulation in INS-1 cell culture medium 
following treatment with recombinant SCF for varying time-points. 
INS-1 cells were cultured in 12-well plates and treated with recombinant SCF at a 
concentration of 50 ng/mL, determined to be sufficient in eliciting a VEGF-A secretory 
response, at time points of 1h, 6h, and 24 h. Culture medium was collected at all time-
points, along with culture medium of untreated time-matched controls, and analyzed for 
VEGF-A content with the Rat VEGF mini ELISA kit. Data are expressed aspictograms per 
milliliter in means ± SD (n=4; **p < 0.01, ***p < 0.001 vs. control group determined by 
one-way ANOVA with Fisher’s Least Significant Difference post-hoc test).  
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Figure 3.4 The mRNA levels of Hif-1α and Vegf-A, total protein level of VEGF-A 
incultured INS-1 cells following SCF treatment. 
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium 
overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL for 
24 hours. RNA and protein were harvested analyzed. (A) qRT-PCR analysis of total 
Vegf-A and Hif-1α mRNA levels in untreated controls and SCF-treated groups. Extracted 
RNA was purified by the RNAqueous-4PCR kit and analyzed using the iQ SYBR Green 
Supermix kit. Data are expressed as means ± SD (n=4; *p < 0.05 vs. controls determined 
by unpaired Student’s t-test) (B) Western blot analysis of VEGF-A protein level 
comparison between untreated controls and SCF-treated groups, normalized to GAPDH. 
Data are expressed as means ± SD (n=3).  
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Figure 3.5 The number of VEGF-A
+
 and insulin
+
 cells in SCF-treated INS-1 cells.  
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium 
overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL for 
24 hours. Cells were harvested and fixed in 4% paraformaldehyde (PFA), then embedded 
in 2% agarose gel, and processed into paraffin blocks, which were then cut into sections 
with a microtome onto glass slides. Sections were then immunolabeled with anti-VEGF-
A (Cy2, green) and anti-insulin (Cy3, red). Nuclei were labeled with with 4’,6-diamidino-
2—phenylindole (DAPI, blue). (A) Representative images for VEGF-A and insulin co-
localization are shown. Scale bar: 5 μm. (B) Morphometric analysis of the total number 
of INS-1 cells co-expressing VEGF-A and insulin 24 h following treatment by SCF [50 
ng/mL]. Data are expressed as percentage of counted cells in means ± SD (n=3; ** p < 
0.01 vs. controls determined by unpaired Student’s t-test). (C) Morphometric analysis of 
total number of INS-1 cells positive for VEGF-A and negative for insulin (left), and total 
number of INS-1 cells negative for VEGF-A and positive for insulin. Data are expressed 
as means ± SD (n=3; * p < 0.05, ** p < 0.01vs. controls determined by unpaired 
Student’s t-test).  
 
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
51 
 
3.5 SCF/c-Kit Regulation of VEGF-A Production is Associated 
with PI3K/Akt/mTOR and Gsk3β/β-catenin Signaling 
To investigate which intracellular signaling pathways are involved in regulating VEGF-A 
production, we examined signaling molecules downstream of c-Kit. INS-1 cells treated 
with 50 ng/mL SCF for 24 h showed significantly increased phosphorylation of c-Kit at 
tyrosine residue 719 when compared to controls (p < 0.05, Figure 3.6A). The 
PI3K/Akt/mTOR axis downstream of c-Kit was examined and it was found that levels of 
Akt phosphorylated at serine residue 473 were significantly increased in the SCF-treated 
cells compared to controls (p < 0.01, Figure 3.6B), and levels of mTOR phosphorylated 
at serine residue 2448 were also significantly increased in the SCF-treated cells, (p < 
0.01, Figure 3.7A). mTOR activation was further confirmed by determining 
phosphorylation of its target, P70S6K, at threonine residue 389, which also exhibited 
increased activation when compared to controls (p < 0.05, Figure 3.7B). Activation of 
mTOR has been linked to activation of a variety of transcription factors, including 
NfκBp65 (Dan et al., 2008; Radhakrishnan et al., 2013). NfκBp65 itself has been 
implicated in the progression of a variety of cancers by its involvement in stimulation of 
angiogenic processes and, specifically, VEGF regulation at the mRNA level (Leibovich 
et al., 2002; Shibata et al., 2002). Thus, phosphorylation of NfκBp65 at serine residue 
536 was assessed and shown to be significantly increased in SCF-treated groups, when 
compared to controls (p < 0.05, Figure 3.7C). These data demonstrate that exogenous 
SCF stimulation of c-Kit activation, results in activation of the PI3K/Akt/mTOR 
signaling pathway. 
Previous studies in our laboratory showed that activation of c-Kit in β-cells leads to an 
increase in Gsk3β phosphorylation at serine residue 9 (Feng et al., 2012).  Inactivating 
Gsk3β by phosphorylation allows for increased activation of β-catenin, a known 
inhibitory target of Gsk3β and a molecule with several consensus binding sites for the 
gene promoter of VEGF-A (Easwaran et al., 2003; Skurk et al., 2005). Gsk3β 
phosphorylation was assessed and, in comparison to controls, exhibited an increased level 
of phosphorylation following SCF stimulation (p < 0.01, Figure 3.8A). Total β-catenin 
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levels were also found to be significantly more abundant in SCF-treated group (p < 0.05, 
Figure 3.8B). These results suggest that SCF/c-Kit interactions increase Akt activation, 
leading to inactivation of Gsk3β and an increase in biologically active β-catenin, which is 
able to interact with VEGF promoters to produce VEGF-A. Taken together, these results 
suggest that, by targets downstream of the PI3K/Akt/mTOR pathway, SCF-mediated c-
Kit activation resulted in increased production of VEGF-A. 
3.6 SCF/c-Kit-mediated VEGF-A Production via Activation of 
Alternative Pathways 
c-Kit activation has been found to stimulate increased activation of other pathways that 
converge onto the PI3K/Akt/mTOR axis and are able to synergistically enhance the 
downstream effects of this pathway (Ronnstrand, 2004). Two proteins in the MAPK 
signaling pathway, p38 and p44/42, are thought to be involved as a result of SCF/c-Kit 
interactions. Thus, we aimed to investigate whether this pathway might impose 
convergent action on stimulating VEGF production (Jin et al., 2005; Kuang et al., 2008). 
There was no change in p44/42 phosphorylation (Figure 3.9A), but levels of 
phosphorylated p38 at tyrosine residues 180 and 182 were increased in the SCF-treated 
group (p < 0.05, Figure 3.9B). These results suggest that activation of MAPK/p38 
converges on targets in the PI3K/Akt/mTOR pathway, possibly eliciting synergistic 
stimulation of VEGF-A production.  
3.7 Pharmacological Inhibition of PI3K and mTOR Attenuated 
the Release of VEGF-A Following SCF Treatment 
To further demonstrate that VEGF-A production and release are dependent on the 
PI3K/Akt/mTOR pathway, VEGF-A release was measured following treatment with a 
combination of SCF 50 ng/mL, and various dosages of the PI3K inhibitor, Lys294002 (0-
100 μmol/L), or the mTOR inhibitor, rapamycin (0-100 nmol/L). It was noted that INS-1 
cells treated with Lys294002 or rapamycin at different dosages for 24 h showed no effect 
on cell loss (Appendix I), however, VEGF-A levels in culture medium were altered in a 
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dose-dependent fashion (Figure 3.10, 3.11). It was found that enhanced VEGF-A release 
stimulated by treatment with 50 ng/mL SCF was abolished when 10 μmol/L of 
Lys294002 was added (Figure 3.10C). Similarly, SCF-stimulated VEGF-A release was 
abolished when cells were treated with rapamycin at dosage of 20 nmol/L (Figure 
3.11C). These results further verify that, despite SCF-stimulated activation of c-Kit, the 
inhibition of key targets along the PI3K/Akt/mTOR pathway resulted in a loss of VEGF-
A accumulation in culture medium and, thus, SCF/c-Kit downstream PI3K/Akt/mTOR 
pathways are responsible for regulating VEGF-A production. 
3.8 Knockdown of c-Kit Expression in the INS-1 Cell Line by c-
Kit siRNA Transfection 
INS-1 cells were transiently transfected with either c-Kit (r) siRNA or control siRNA to 
examine the effect of c-Kit down-regulation on VEGF-A production. Following siRNA 
treatment for 48 to 72 hours, the expression of c-Kit mRNA, protein and phosphorylation 
were determined. Following 48 h of transfection culture, c-Kit mRNA expression was 
reduced ~45%, as determined by qRT-PCR, but did not reach statistical significance 
(Figure 3.12A). There was a significant decrease in the amount of total c-Kit protein 
after 72 h of c-Kit (r) siRNA-transfection in INS-1 cells compared to those treated with 
control siRNA (p < 0.05, Figure 3.12B). We further examined the levels of phosphor-c-
Kit at 72 h of c-Kit(r) siRNA-transfected cells and observed a reduction in c-Kit 
activation (Figure 3.12C).  These data verified that siRNA treatment mediated c-Kit 
knockdown at both the mRNA and protein level, allowing for analysis of further 
downstream targets. 
3.9 Expression of VEGF-A Production in INS-1 Cells Following 
siRNA-mediated c-Kit Knockdown 
Forty-eight hours following c-Kit (r) siRNA-mediated knockdown in INS-1 cells, levels 
of Hif-1α and Vegf-A mRNA were assessed by qRT-PCR analysis. It was found that 
transcript levels of both Hif-1α and Vegf-A trended toward a decrease, though did not 
54 
 
reach significance (Figure 3.13A). After 72 hours of transfection, western blot analysis 
of intracellular VEGF-A content was reduced ~21% in the c-Kit (r) siRNA-treated group 
compared to control siRNA group, though was not significantly different (Figure 3.13B). 
VEGF-A release into the culture medium, analyzed by a rat VEGF mini ELISA kit, 
showed non-significant, minimal reduction compared to controls (Figure 3.13C), 
indicating that down-regulation of c-Kit expression by siRNA affects VEGF-A 
production. We further examined the number of VEGF-A-positive and insulin-positive 
cells in both experimental groups and found neither double-positive cell nor single-
positive cell populations had changed (Figure 3.14). 
3.10 Knockdown of c-Kit Inhibits the PI3K/Akt/mTOR Signaling 
Pathway 
The downstream PI3K/Akt/mTOR axis was assessed in order to confirm down-regulation 
of signaling molecules downstream of c-Kit after a 72 h c-Kit siRNA transfection. Levels 
of Akt phosphorylated at serine residue 473 were significantly decreased in the 
knockdown cells, compared to controls (p < 0.05, Figure 3.15A), and levels of mTOR 
phosphorylated at serine residue 2448 were also significantly decreased in the c-Kit 
siRNA knockdown cells, compared to controls (p < 0.05, Figure 3.15B). mTOR 
activation was further confirmed by assaying phosphorylation of its well-established 
target, P70S6K, at threonine residue 389, which also exhibited decreased activation when 
compared to controls (p < 0.01, Figure 3.15C). Phosphorylation of NfκBp65 at serine 
residue 536 was found to be significantly decreased in c-Kit knockdown groups, when 
compared to controls (p < 0.05, Figure 3.15D). These analyses confirmed that 
knockdown of c-Kit expression resulted in decreased activation of molecules along the 
PI3K/Akt/mTOR pathway. 
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3.11 Inactivation of Downstream Targets of Akt and p38 inhibit 
VEGF-A Production and Release 
Further signaling molecules downstream of the PI3K/Akt pathway were examined in 
order to provide a linkage specifically to decreased VEGF-A production in these cells, 
due to knockdown of c-Kit by siRNA transfection. Gsk3β phosphorylation was 
decreased, suggesting that its activation was increased, following knockdown of c-Kit 
compared to controls (p < 0.05, Figure 3.16A). Upon analysis, total β-catenin levels were 
shown to decrease significantly in abundance in the knockdown groups (p < 0.05, Figure 
3.16B). As mentioned in section 3.8, p38 MAPK is thought to work synergistically to 
activate mTOR alongside the PI3K/Akt pathway and, ultimately, increase VEGF-A 
production. In the case of siRNA-mediated knockdown, it was found that p38 MAPK 
protein levels trended toward decrease, but did not reach significance (Figure 3.16C). 
Taken together, these results suggest that by inhibition of targets downstream of the 
PI3K/Akt/mTOR pathway, c-Kit knockdown results in the decreased production of 
VEGF-A. 
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Figure 3.6  Protein analysis of c-Kit and Akt activation in cultured INS-1 cells treated 
with SCF.  
INS-1 (832/13) cells were cultured in 12-well plates containing RPMI-1640 1% BSA 
medium overnight, and treated with human recombinant SCF at a concentration of 50 
ng/mL for 24 hours. Cells were incubated in Nonidet-P40 lysis buffer and dispersed by 
sonication to extract protein. c-Kit and Akt phosphorylation was compared by western blot 
analysis, with representative images of western blots shown on top of graphs. Proteins 
assayed include (A) Phosphorylated (Tyr719) c-Kit compared to total c-Kit, (B) 
phosphorylated (Ser473) Akt compared to total Akt. Data are normalized to total protein 
levels and expressed as fold versus control (means ± SD; n=3-4; * p < 0.05, ** p < 0.01 vs. 
controls analyzed by unpaired Student’s t-test).  
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Figure 3.7 Protein analysis of mTOR activation and its downstream targets, P70S6K 
and NfκBp65 in cultured INS-1 cells treated with SCF.  
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium 
overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL for 24 
hours. Cells were incubated in Nonidet-P40 lysis buffer and dispersed by sonication to extract 
protein. mTOR, P70S6K and NfκB phosphorylation was compared by western blot analysis, 
with representative images of western blots shown on top of graphs. Proteins assayed include 
(A) Phosphorylated (Ser2448) mTOR compared to total mTOR, (B) phosphorylated (Thr389) 
p70S6K compared to total p70S6K, (C) phosphorylated (Ser536) NfκBp65 compared to total 
NfκBp65. Data are normalized to total protein levels and expressed as fold versus control 
(means ± SD; n=3-4; * p < 0.05, ** p < 0.01 vs. controls analyzed by unpaired Student’s t-
test).  
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Figure 3.8 Protein analysis of activated Gsk3β and total β-catenin in cultured INS-1 
cells treated with SCF.  
INS-1 (832/13) cells were cultured in 12-well plates containing RPMI-1640 1% BSA 
medium overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL 
for 24 hours. Cells were incubated in Nonidet-P40 lysis buffer and dispersed by sonication to 
extract protein. Gsk3β phosphorylation and total β-catenin were compared by western blot 
analysis, with representative images of western blots shown on top of graphs. Proteins 
assayed include (A) phosphorylated (Ser9) Gsk3β compared to total Gsk3β, (B) total β-
catenin compared to housekeeping protein GAPDH. Data are normalized to total protein 
levels or GAPDH and expressed as fold versus control (means ± SD; n=3-4; * p < 0.05, ** p 
< 0.01 vs. controls analyzed by unpaired Student’s t-test).  
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Figure 3.9 Protein analysis of activated p42/44 MAPK and p38 MAPK in cultured INS-1 
cells treated with SCF.  
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium 
overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL for 24 
hours. Cells were incubated in Nonidet-P40 lysis buffer and dispersed by sonication to extract 
protein. p42/44 MAPK and p38 MAPK phosphorylation was compared by western blot 
analysis, with representative images of western blots shown on top of graphs. Proteins assayed 
include (A) phosphorylated (Thr202/Tyr204) p42/44 MAPK compared to total p42/44 MAPK 
(B) phosphorylated (Thr180/Tyr182) p38 MAPK compared to total p38 MAPK. Data are 
normalized to total protein levels and expressed as fold versus control (means ± SD; n=3-4; * p 
< 0.05vs. controls analyzed by unpaired Student’s t-test).  
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Figure 3.10 VEGF-A secretion in SCF-treated cultured INS-1 cells with and 
without varying concentrations of a PI3K inhibitor (Lys294002).  
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium 
overnight. Fresh medium was added to wells, and cells were cultured with Lys294002 in 
increasing concentrations [0, 1, 10, 100 umol/L], with human recombinant SCF [50 
ng/mL] or an SCF vehicle for a period of 24 h. At the end of the culture period, culture 
medium was collected and analyzed for VEGF-A secretion. VEGF-A secretion analyses 
are shown for (A) control and SCF-treated, (B) Lys294002 1 umol/L with or without 
SCF, (C) Lys294002 10 umol/L with or without SCF, (D) Lys294002 100 umol/L with 
or without SCF. The Rat VEGF mini ELISA kit was used to quantify data. Data are 
normalized to total protein levels and expressed as fold versus control (means ± SD; 
n=3;** p < 0.01 SCF vs control determined by unpaired Student’s t-test).  
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Figure 3.11 VEGF-A release in untreated and SCF-treated cultured INS-1 cells with 
and without varying concentrations of an mTOR inhibitor (rapamycin).  
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium 
overnight. Fresh medium was added to wells, and cells were pre-treated with increasing 
concentrations of rapamycin [0, 5, 20, 100 nmol/L] for 30 minutes prior to treatment with 
either human recombinant SCF [50 ng/mL] or an SCF vehicle for a period of 24 hours. 
At the end of the culture period, cell medium was collected and analyzed for VEGF-A 
secretion. VEGF-A secretion analyses are shown for (A) control and SCF-treated, (B) 
rapamycin 5 nmol/L with and without SCF, (C) rapamycin 20 nmol/L with and without 
SCF, (D) rapamycin 100 nmol/L with and without SCF. The Rat VEGF mini ELISA kit 
was used to quantify data. Data are expressed as means ± SD (n=3; * p < 0.05, *** p < 
0.001 SCF vs. control determined by unpaired Student’s t-test).  
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Figure 3.12 c-Kit expression in cultured INS-1 cells following siRNA-mediated c-Kit 
knockdown.  
INS-1 cells were cultured on 12-well plates and treated with either c-Kit (r) siRNA or control 
siRNA transfection mixtures. Transient transfection took place for either 48 h or 72 h. mRNA 
was harvested from cells after 48 h of transient transfection with the RNAqueous-4PCR kit. 
(A) RT-PCR images showed expression of c-Kit and 18S captured under UV light and qRT-
PCR analysis of c-Kit mRNA at 48 h of culture. Data are expressed as fold-change vs. control 
siRNA group (n=3). Following 72 h of transient transfection, cells were incubated in Nonidet-
P40 lysis buffer and dispersed by sonication to extract protein. Extracted protein was analyzed 
from both groups by western blot analysis, with representative images of western blots shown 
on top of graphs. (B) Total c-Kit levels were normalized to housekeeping protein GAPDH, (C) 
Phosphorylated (Tyr 719) c-Kit levels were normalized to housekeeping protein GAPDH. Data 
are expressed as fold versus control (means ± SD; n=3; * p < 0.05, ** p < 0.01 vs. control 
siRNA group determined by unpaired Student’s t-test). 
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Figure 3.13 Total mRNA levels of Hif-1α and Vegf-A, protein level of VEGF-A, and 
VEGF-A secretion of cultured INS-1 cells following c-Kit siRNA treatment.  
INS-1 cells were cultured in 12-well plates containing RPMI-1640 10% FBS medium 
overnight, and treated with either c-Kit (r) siRNA or control siRNA for 48 h or 72 h. RNA 
was harvested at 48 h, while cellular protein and culture medium were were collected after 
72 h and analyzed. (A) qRT-PCR analysis of total Vegf-A and Hif-1α mRNA levels in 
controls and c-Kit siRNA-treated groups. Extracted RNA was purified by the RNAqueous-
4PCR kit and analyzed using the iQ SYBR Green Supermix kit. Data are expressed as 
means ± SD (n=5) (B) Western blot analysis of VEGF-A protein level comparison 
between controls and c-Kit siRNA-treated groups. Data are normalized to GAPDH and 
expressed as fold versus control (means ± SD; n=3). (C) Analysis of VEGF-A secretion 
into medium after 72 h of siRNA-mediated c-Kit knockdown. The Rat VEGF mini ELISA 
kit was used to quantify data. Data are expressed as means ± SD (n=6).  
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Figure 3.14 The number of VEGF-A
+
 and insulin
+
 cells in c-Kit  siRNA and control 
siRNA-treated INS-1 cells.  
INS-1 cells were cultured in 12-well plates containing RPMI-1640 10% FBS medium 
overnight, and treated with either c-Kit (r) siRNA or control siRNA for a period of 72 h. 
Cells were harvested and fixed in 4% paraformaldehyde (PFA), then embedded in 2% 
agarose gel, and processed into paraffin blocks, which were then cut into sections with a 
microtome onto glass slides. Sections were then immunolabeled with anti-VEGF-A (Cy2, 
green) and anti-insulin (Cy3, red). Nuclei were labeled with with 4’,6-diamidino-2—
phenylindole (DAPI, blue). (A) Representative images for VEGF-A and insulin co-
localization are shown. Scale bar: 5 μm. (B) Morphometric analysis of the total number of 
INS-1 cells co-expressing VEGF-A and insulin 72 h following treatment by c-Kit siRNA. 
(C) Morphometric analysis of total number of INS-1 cells positive for VEGF-A and negative 
for insulin (left), and total number of INS-1 cells negative for VEGF-A and positive for 
insulin. Data are expressed as means ± SD (n=3).  
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Figure 3.15 Protein analysis of Akt, mTOR, P70S6K, NfκBp65 activation in cultured 
INS-1 cells treated with c-Kit siRNA.  
INS-1 cells were cultured in 12-well plates containing RPMI-1640 10% FBS medium 
overnight, and treated with either c-Kit (r) siRNA or control siRNA for 72 h. Cells were 
incubated in Nonidet-P40 lysis buffer and dispersed by sonication to extract protein. Akt, 
mTOR, P70S6K, and NfκBp65 phosphorylation was compared by western blot analysis, with 
representative images of western blots shown on top of graphs. Proteins assayed include (A) 
Phosphorylated (Ser473) Akt compared to total Akt, (B) phosphorylated (Ser2448) mTOR 
compared to total mTOR, (C) phosphorylated (Thr389) P70S6K compared to total P70S6K, 
(D) phosphorylated (Ser536) NfκBp65 compared to total NfκBp65. Data are normalized to 
total protein levels and expressed as fold versus control (means ± SD; n=3-4; * p < 0.05, ** p 
< 0.01 vs. control siRNA groups analyzed by unpaired Student’s t-test).  
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Figure 3.16 Protein analysis of Gsk3β activation, total β-catenin, and p38 MAPK 
activation in cultured INS-1 cells treated with c-Kit siRNA.  
INS-1 cells were cultured in 12-well plates containing RPMI-1640 10% FBS medium 
overnight, and treated with either c-Kit (r) siRNA or control siRNA for 72 h. Cells were 
incubated in Nonidet-P40 lysis buffer and dispersed by sonication to extract protein. Gsk3β 
phosphorylation, total levels of β-catenin, and phosphorylation of p38 MAPK was compared 
by western blot analysis, with representative images of western blots shown on top of graphs. 
Proteins assayed include (A) Phosphorylated (Ser9) Gsk3β compared to total Gsk3β, (B) total 
β-catenin compared to housekeeping protein GAPDH, (C) phosphorylated (Thr180/Tyr182) 
p38 MAPK compared to total p38 MAPK. Data are normalized to total protein levels or 
GAPDH and expressed as fold versus control (means ± SD; n=3-4; * p < 0.05 vs. control 
siRNA analyzed by unpaired Student’s t-test). 
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Chapter 4  
4 Discussion 
The objective of this thesis was to investigate the functional role of c-Kit in the regulation 
of β-cell VEGF-A production and associated intracellular signaling pathway using the 
INS-1 cell line as an in vitro model.  The hypothesis was that an increase in c-Kit 
activation could stimulate VEGF-A production in β-cells via the PI3K/Akt/mTOR 
pathway. The results presented in this study highlight that there is a significant increase 
in VEGF-A release, a factor required for islet vessel formation, in INS-1 cells following 
stimulation with exogenous SCF. This effect was mediated by upregulation of 
phosphorylated c-Kit and its downstream targets along the PI3K/Akt/mTOR signaling 
pathway. Cells treated with SCF plus either a PI3K inhibitor (Lys294002) or mTOR 
inhibitor (rapamycin) displayed an attenuation in VEGF-A levels in culture medium, 
providing further evidence that activation of c-Kit and its downstream PI3K/Akt/mTOR 
signaling pathway is essential for VEGF-A modulation (Figure 4.1). Conversely, INS-1 
cells treated with c-Kit siRNA demonstrated that knockdown of c-Kit expression results 
in a decrease of phosphorylation along the Akt/mTOR pathway and, consequently, 
decreased production and release of VEGF-A. Taken together, these findings lay down 
the groundwork suggesting that the c-Kit receptor tyrosine kinase and downstream targets 
of the PI3K/Akt/mTOR axis exert a regulatory effect on VEGF-A production and release 
in β-cells in vitro.  Further investigation of c-Kit-mediated VEGF-A production and 
function using exogenous SCF to stimulate isolated murine islets, and in vivo models 
with transgenic c-Kit over-expression (c-KitβTg) or c-Kit knockdown by point-mutation 
(Wv) would enhance our understanding of vascular defects in the diabetic state and 
provide insight in the process of restoring vasculature following islet transplantation in 
T1DM. This could be accomplished by assessing and comparing c-Kit knockdown and 
overexpression models’ vasculature and pancreatic function by protein and RNA analysis 
from isolated islets, as well as vasculature morphology through PECAM-1 or collagen IV 
staining, then examing whether crossing the two mouse models would result in recovery 
of vascular impairment. 
79 
 
  
Figure 4.1 Schematic of proposed model involving SCF-stimulated c-Kit activation 
through the convergence of the PI3K/Akt and p38 MAPK pathways to increase 
VEGF-A production. 
SCF binding to the receptor tyrosine kinase c-Kit results in homodimerization of the 
receptor and subsequent autophosphorylation on tyrosine residue 719. This allows for 
recruitment of PI3K/Akt via its pleckstrin homology (PH) domain and phosphorylation of 
Akt at serine residue 473, resulting in its kinase activity. Akt is able to direct 
phosphorylation of mTOR on serine residue 2448, allowing it to bind to Raptor protein, 
forming the bioactive mTORC1 complex, and/or phosphorylate Gsk3β at serine residue 9 
to inactivate it. The mTORC1 complex is then able to act upon NfκBp65 at serine residue 
534, resulting in its translocation to the nucleus and increased transcription of HIF-1α, a 
transcription factor that promotes VEGF-A production and secretion. Inactivated Gsk3β 
is unable to degrade β-catenin which allows β-catenin to translocate into the nucleus and 
promote increased VEGF-A transcription. p38 MAPK is another molecule that is 
activated when bound via its SH2 domain to activated c-Kit. p38 MAPK is then 
phosphorylated at threonine residue 180 and tyrosine residue 182, allowing it to further 
stimulate mTOR phosphorylation and mTORC1’s downstream effects. 
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4.1 Do c-Kit and VEGF-A Co-localize in SCF-treated INS-1 
Cells? 
It has been reported that c-Kit is expressed in INS-1 cells (Rachdi et al., 2001), the cell 
line used in this work. Previous reports showed that SCF and VEGF are co-localized in 
cancer cells derived from human metastatic melanoma (Heissig et al., 2003). In order to 
confirm that c-Kit and VEGF-A are located in the same cell population, we first used 
double immunofluorescence staining to show the co-localization of VEGF-A and c-Kit in 
INS-1 cells. Our data from live cell staining on cover slips demonstrated that both c-Kit 
and VEGF-A co-localized in these cells, but distribution differed (Figure 3.1). c-Kit 
expression was located primarily near cell membranes, with some staining of internalized 
c-Kit receptors, while VEGF-A stained predominantly in the cytoplasm of cells. These 
data built a case which prompted us to examine whether there is a relationship between 
activation of the c-Kit receptor and modulation of VEGF-A production in the following 
experiments.  
4.2 Can VEGF-A Production and Release be Stimulated by 
Exogenous SCF Activaiton of c-Kit in vitro? 
Upon treatment with SCF at a variety of concentrations, a VEGF-A ELISA determined 
that there was, in fact, an increase in VEGF-A release in a dose- and time dependent 
fashion into cell culture medium after SCF treatment (Figure 3.2 and 3.3). A significant 
increase in culture medium VEGF-A levels was observed at 24 h of SCF-stimulation 
compared to controls (Figure 3.3). This delayed response was likely due to the fact that 
INS-1 is a cancer cell line and contains a high basal level of VEGF-A production and 
release, compared to that found in isolated islets or animal models. Despite the fact that 
cancer cell lines, such as INS-1, have a high basal VEGF-A secretion rate (Bellamy et al., 
1999; Dankbar et al., 2000), previous studies have used this cell line to demonstrate 
quantifiable stimulation of VEGF-A production and secretion, specifically by the 
induction of HIF-1α by oxidative stress (Moritz et al., 2002; Gosh et al., 2010). A study 
reported that HIF-1α expression was upregulated following SCF stimulation in a 
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hemetopoietic cell line, which yielded a transcriptionally active form of HIF-1α, able to 
modulate VEGF, induced through stimulation of c-Kit and subsequent activation of the 
PI3K and Ras/MEK/Erk pathways (Pedersen et al., 2008). Similarly, observations made 
in our study demonstrated that INS-1 cells treated with SCF exhibited significantly 
increased levels of Hif-1α and Vegf-A mRNA (Figure 3.4A) and VEGF-A release 
(Figure 3.2, 3.3). Intracellular VEGF-A content was shown to increase ~25%, but did not 
reach statistical significance (Figure 3.4B). One possible explanation for this observation 
is that increased VEGF-A production was secreted immediately in response to 
physiological stimuli, as demonstrated in cultured mouse islets responding to low glucose 
culture conditions (Xiao et al., 2013). Furthermore, performing this study under hypoxic 
conditions would likely exacerbate VEGF-A production and secretion due to a lack of 
VHL-mediated inhibition and degradation of factors such as HIF-1α that serve to 
promote angiogenic processes. 
The mechanism by which VEGF-A is secreted from β-cells is not well-understood but it 
has been reported that, in bone marrow-derived mast cells, release of VEGF-A is largely 
mediated by hypoxia-triggered signaling pathways that depend on the Src family kinases 
and PI3K (Garcia-Roman et al., 2010). Furthermore, in a VEGF reporter study performed 
in Hep3B cells, it was demonstrated that the 5’-flanking region of the VEGF gene is able 
to functionally interact with HIF-1, composed of the HIF-1α and HIF-1β subunits, on at 
least two HIF-1 binding sites (Forsythe et al., 1996), further implicating HIF-1α as a key 
regulator of VEGF-A . We have previously shown, in vitro and in vivo, that c-Kit 
activation by SCF could target the PI3K/Akt signaling pathway (Li et al., 2006; Feng et 
al., 2011; Feng et al., 2012). It was thought that SCF-induced VEGF-A release in INS-1 
cells might also be regulated by activation of c-Kit and downstream of the PI3K/Akt 
signaling pathway as discussed below.  
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4.3 Is the PI3K/Akt/mTOR Signaling Pathway Involved in 
VEGF-A Regulation? 
4.3.1 c-Kit Receptor Phosphorylation 
c-Kit is able to mediate a variety of effects on various cell types in a variety of cell 
lineages and cell types in murine and human models. Upon ligand-binding, the 
transmembrane receptor is phosphorylated on tyrosine residue 719 in the kinase insert 
region, allowing it to associate with the p85 subunit of PI3K, containing two SH2 
domains, to induce its phosphorylation and activation of more downstream signaling 
molecules by activity of the 110 kDa catalytic subunit (p110) (Serve et al., 1994; Yee et 
al., 1994). Expectedly, 24 hours following SCF treatment, INS-1 cells had significantly 
increased phosphorylation of c-Kit at tyrosine residue 719, indicating that SCF and c-Kit 
interaction results in activation of the receptor tyrosine kinase (Figure 3.6A). 
4.3.2 Akt Phosphorylation 
Activation of PI3K results in the production of phosphatidylinositol-3,4,5-triphosphate 
(PIP3), which is able to recruit signaling proteins with pleckstrin homology (PH) 
domains, consisting of approximately 100 amino acids, to the membrane, such as Akt 
(Vara et al., 2004). Akt is expressed as three isoforms (Akt1/2/3) that exhibit highly 
overlapping functions in regulation of factors such as cellular growth, glucose 
homeostasis, and neuronal development, and feature many common phosphorylation sites 
due to their shared amino-terminal PH domain (Manning and Cantley, 2007; Gonzalez et 
al., 2009). Recruitment of Akt by PIP3, the lipid product of activated PI3K, results in 
conformational changes in Akt and exposure of two of its essential phosphorylation sites, 
threonine residue 308 and serine residue 473 (Andjelkovic et al., 1995; Kandel et al., 
1999; Brazil and Hemmings, 2001). While phosphorylation of threonine residue 308, 
located within the activation loop of the kinase domain, is required for activation of Akt, 
phosphorylation of serine residue 473, located at the C-terminus, is thought to be required 
for full kinase activity (Kandel et al., 1999; Widenmaier et al., 2009). 3-
phosphoinositide-dependent kinase (PDK1), a PIP3-dependent kinase, is responsible for 
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phosphorylation of threonine residue 308, while phosphorylation of serine residue 473 
has been shown to be dependent on the mTOR complex 2 (mTORC2), containing mTOR, 
rictor, and mLST8 (Hresko et al., 2005; Sarbassov et al., 2006). PDK1 and mTORC2 
activity play a role in a variety of cellular processes including cell death regulation, cell 
cycle progression, and cell growth (Juan et al., 2004). Our lab has previously determined 
that activation of c-Kit led to phosphorylation of Akt at serine residue 473, but not 
threonine residue 308 (Feng et al., 2011). Therefore, we examined phosphorylation of 
Akt on serine residue 473 after SCF stimulation, which showed a significant increase in 
the activity of Akt in association with VEGF-A release (Figure 3.6B). Lys294002 was 
used as a potent inhibitor of PI3K, and it was found that VEGF-A release was attenuated 
to control levels at a sufficient dosage (10 μmol/L) despite SCF stimulation (Figure 
3.10C). This further confirmed the involvement of the Akt signaling pathway in SCF-
stimulated VEGF-A release. However, whether PDK1 and mTORC2 activity is involved 
in this regulatory process was not examined in this work, thus it would be important to 
investigate in future research in order to verify whether SCF/c-Kit-induced VEGF-A 
release requires activation of multiple downstream kinases. 
4.3.3 mTOR Signaling Pathway 
The mammalian target of rapamycin (mTOR) is the most-examined downstream 
substrate of Akt. Akt exerts a number of mechanisms to regulate mTOR, either directly 
through phosphorylation of the substrate, or by modulation of other regulatory 
mechanisms. Akt is able to indirectly activate mTOR through phosphorylation of 
tuberous sclerosis complex 2 (TSC2) resulting in its inhibition and inability to 
heterodimerize with tuberous sclerosis complex 1 (TSC1) (Inoki et al., 2003; Tee et al., 
2003). Once TSC2 is inhibited and unable to form its active complex with TSC1, it is 
unable to hydrolize GTP to GDP in Ras homolog enriched in brain (Rheb). Without this 
negative regulation of Rheb, it is able to remain in its GTP-bound state, allowing for 
increased activation of mTOR (Inoki et al., 2003; Manning and Cantley, 2003). It has 
been proposed that for full TSC2 inactivation, Akt must play a role in regulation, through 
direct inhibition of TSC2 by phosphorylation, which it can also influence by increasing 
ATP levels (Hahn-Windgassen et al., 2005). In this work, mTOR activation was assayed 
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by examining phosphorylation of serine residue 2448, which has been demonstrated to be 
crucial in Akt-mediated mTOR activation (Nave et al., 1999; Inoki et al., 2002). As 
expected, due to increased activation of Akt, mTOR phosphorylation/activation was 
significantly increased following SCF treatment in INS-1 cells (Figure 3.7A). Inhibiting 
the mTOR pathway with rapamycin at a sufficient dosage (20 nmol/L) could block SCF-
induced VEGF-A release in INS-1 cells (Figure 3.11C). Furthermore, it has been shown 
that insulin binding to its receptor increases Akt-mediated phosphorylation of TSC2 at 
serine residues 939 and 981, resulting in the dissociation of the TSC1/2 complex (Cai et 
al., 2006). Since INS-1 cells are able to produce greater amounts of insulin, and c-Kit 
activation has been linked to increased insulin production and expression (Rachdi et al., 
2001), it is possible that mTOR activation was compounded by these factors, creating an 
even stronger response than hypothesized. Thus, it would be critical, for future study, to 
examine the effect of c-Kit activation on the TSC1/2 complex in this context. mTOR can 
bind to Raptor to form the mTORC1 complex, controlled by GTP-bound Rheb amongst 
other signaling molecules, or mTOR can bind to Rictor to form the mTORC2 complex, 
which is activated by a variety of RTKs and can interact with Akt to regulate it 
(Sarbassov et al., 2005). The exact function and mechanism by which mTORC2 is 
activated and exerts its effects is not well-known, but in this work, mTORC1 and its 
downstream effects are of particular relevance to VEGF-A regulation in INS-1 cells. 
4.3.4 P70S6K and NfκB of the mTOR-targeted Signaling Pathway 
mTOR is an important regulator of a variety of cellular functions, including cell growth 
and proliferation. It is located downstream of the PI3K/Akt pathway, and its most 
important substrate is p70S6K. Overall the pathway is implicated not only in cell 
proliferation, growth, differentiation and survival (Schmelzle and Hall, 2000), but also 
angiogenesis and tumor neovascularisation, making it a likely candidate for VEGF-A 
modulation in our current study (Maffucci et al., 2005). Once the mTORC1 complex is 
formed, mediated by Rheb due to the Akt-mediated inhibition of TSC2, it can act upon 
the hydrophobic motif of p70S6K, phosphorylating it at threonine residue 389, an effect 
that is confirmed to be attenuated in siRNA-mediated PI3K p110 catalytic subunit 
knockdown (Matheny and Adamo, 2009). In this work, phosphorylated p70S6K was 
86 
 
significantly increased following SCF treatment in INS-1 cells, further confirming the 
functional activation of mTOR (Figure 3.7B). It should be noted that P70S6K can also be 
regulated by phosphorylation of threonine residue 229 by PDK1, which also serves as a 
regulatory protein in PI3K signaling (Pullen et al., 1998). In future work, PDK1 activity 
should be analyzed to ensure changes in mTOR signaling are indeed modulated by c-Kit-
mediated PI3K/Akt activation. 
In addition to p70S6K, mTOR is also able to target the transcription factor NfκB, first 
identified as a nuclear factor that binds the κ light chain enhancer in B-cells, but thought 
to have a role in a variety of cellular functions including angiogenic processes and 
immune responses (Jung et al., 2003B; Shinojima et al., 2007). NfκB signal transduction 
is reliant on phosphorylation and degradation of the IκB protein by the IKK complex, 
consisting primarily of IKKα and IKKβ. Once the IKK complex phosphorylates the IκB 
protein, it is marked for proteasomal degradation, allowing for NfκB to migrate to the 
nucleus and bind to target sequences (Hayden and Gosh, 2004). It has been reported that 
Akt is able to activate NfκB transcriptional activity (Madrid et al., 2001; Sizemore et al., 
2002) and direct its nuclear accumulation (Gustin et al., 2004). A study has demonstrated 
that insulin is important in mediating an interaction between mTOR and IKKα, which is 
essential for NfκB transcriptional modulation (Dan and Baldwin, 2008). NfκBp65 has 
been shown, in normoxic conditions, to respond to activation by the PI3K/Akt/mTOR 
axis and mediate HIF-1α transcription, thought to be a driving force in VEGF-A 
regulation (Jung et al., 2003a; Jung et al., 2003b; Bonello et al., 2007). It has been 
demonstrated that NfκBp65 is phosphorylated at serine residue 534, mediated by IκK 
kinase α and β, necessary for releasing NfκB as an active transcription factor, able to 
increase transcription of HIF-1α (Bonello et al., 2007; Bai et al., 2009). In this work, 
NfκBp65 phosphorylation in SCF-treated INS-1 cells was found to be increased and 
transcriptionally active, modulating HIF-1α expression and increasing VEGF-A 
production (Figure 3.7C). 
Taken together, these results suggest that following SCF stimulation of c-Kit in INS-1 
cells, the PI3K/Akt/mTOR axis is able to modulate a variety of downstream signaling 
87 
 
proteins as confirmed by an inhibitory study, in order to increase the production of 
angiogenic transcription factor HIF-1α and promote VEGF-A production and release.  
4.4 Is the Akt/Gsk3β/ β-catenin Signaling Pathway Involved in 
SCF-induced VEGF-A Production and Release in INS-1 
Cells? 
Our lab previously showed that the Akt/Gsk3β signaling pathway plays a key role in 
regulation of β-cell function and survival in both c-Kit mutation and over-expression 
mouse models (Feng et al., 2011; Feng et al., 2012), thus we have investigated whether 
this signaling pathway is also involved in SCF-mediated VEGF-A production in vitro. 
The serine/threonine kinase, glycogen synthase kinase 3 (Gsk3) consists of two highly 
homologous isoforms: Gsk3α and Gsk3β. These isoforms are similarly regulated and able 
to compensate for one another in some functions, sharing nearly identical sequences in 
their kinase domains (Shaw et al., 1997; Jope and Johnson, 2004; Thornton et al., 2008). 
However, studies have indicated that Gsk3β is a substrate that is inactivated by active Akt 
when phosphorylated at the N-terminal serine residue 9 (Shaw et al., 1997; Feng et al., 
2012). Apart from active, unphosphorylated Gsk3β’s ability to regulate glycogen 
synthase, it has been implicated in a variety of cellular processes, mediating cell cycle, 
motility and apoptosis. Its dysregulation has been linked to several pathologies, including 
the onset of cancer and diabetes (Jope and Johnson, 2004). Studies on Gsk3β inhibition in 
isolated adult human and rat islets have indicated that Gsk3β pharmacological 
inactivation results in increased islet cell proliferation (Liu et al., 2009). In vivo, mice 
with a β-cell-specific Gsk3β overexpression displayed reduced β-cell mass and function, 
while mice with a heterozygous c-Kit point-mutation (c-Kit
Wv/+
) were treated with 1-
AKP, a Gsk3β inhibitor, and were able to recover β-cell function, in terms of proliferative 
capacity and insulin secretion, as well as maintain normal glucose processing (Liu et al., 
2008; Feng et al., 2012). Taken together, these studies indicate that Gsk3β inactivation 
plays a crucial role in β-cell function and survival, and is modulated by the PI3K/Akt 
pathway through c-Kit stimulation. We examined the level of Gsk3β phosphorylated at 
serine residue 9 in SCF-treated INS-1 cells and found that its phosphorylation was 
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significantly increased (Figure 3.8A), along with increased total β-catenin (Figure 3.8B), 
indicating that SCF/c-Kit-induced VEGF-A production is associated with Akt/Gsk3β 
phosphorylation. 
It has been shown that modulation of the Gsk3β/β-catenin axis in a variety of cell types 
has resulted in the initiation of several angiogenic processes, including expression of 
VEGF-A/C, and increased phosphorylation of the VEGF receptor 2 (VEGFR-2) (Skurk et 
al., 2005; Leung et al., 2006). Furthermore, studies have demonstrated that Akt is able to 
directly phosphorylate β-catenin at serine residue 552, in vitro and in vivo, causing β-
catenin to dissociate from cell-cell contacts, accumulating in both cytosol and the nucleus 
(Sharma et al., 2002; Fang et al., 2007). Phosphorylation of this site was not examined in 
this work, and would be beneficial to evaluate in future research.  
4.5 Is the MAPK/Erk Signaling Pathway Involved in SCF-
induced VEGF-A Production and Release in INS-1 Cells? 
In addition to stimulation of the PI3K/Akt/mTOR axis by the mechanisms discussed 
previously, there are thought to be other converging pathways by which VEGF-A 
regulation is synergistically controlled from c-Kit activation. It has been reported that 
SCF stimulation in bone marrow stem cells and cardiac stem cells induced cell migration 
due to its ability to activate MAPKs, including ERK1/2, p38 MAPK, and JNK (Kuang et 
al., 2008). There are reports in human bone marrow mesenchymal stem cells and adipose 
progenitor cells are able to produce VEGF, HGF, and IGF-I by a p38 MAPK-dependent 
mechanism (Wang et al., 2006). Additionally, it has been established that p38 MAPK and 
Akt play a synergistic role in mTOR activation, necessary for VEGF-A modulation, in a 
variety of cell types, including the human osteosarcoma cell line SaOS, the human 
fibroblast HCA2 cell line and mouse embryonic fibroblast cell lines (Hernandez et al., 
2011). Based on these reports, levels of p38 MAPK phosphorylation were examined, and 
found to have increased following SCF treatment in INS-1 cells (Figure 3.9B). However, 
the phosphor-Erk42/44 level in SCF-treated INS-1 cells showed no changes (Figure 
3.9A), possibly due to inhibition by NfκB for which it may act as a compensatory 
mechanism (Frede et al., 2006). Additionally, some avenues of research have identified c-
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Kit activation-dependent p42/44 MAPK signaling to peak shortly following c-Kit 
activation (<1 hour), and to attenuate over time in the absence of sustained c-Kit 
activation (Zheng et al., 2011). Moving forward, it would be interesting to examine its 
activity in comparison to the rest of the pathway at a much shorter time-point.  
4.6 Does Down-regulation of c-Kit Expression Affect VEGF-A 
Production? 
To further test whether down-regulation of c-Kit expression could influence VEGF-A 
production and release, a c-Kit siRNA study was performed in this study. In this work 
total c-Kit was found to be significantly reduced (Figure 3.12B) and activated c-Kit, 
phosphorylated at tyrosine residue 719 was significantly reduced (Figure 3.12C).  RT-
PCR analysis for RNA quality showed that there was a ~45% decrease in c-Kit RNA in 
c-Kit siRNA-treated groups, compared to control siRNA-treated groups, but did not reach 
statistical significance (Figure 3.12A). While this is indicative of inefficient transfection, 
likely confounded by growth factors found in the transfection medium and the use of 3 
merged complexes of c-Kit siRNA that may have variable efficiency, it is still possible to 
see a significant effect on downstream pathways due to c-Kit activation’s profound effect 
on β-cell physiology, as demonstrated previously using c-KitWv/+ mice with a 
heterozygous point-mutation which knocked down ~50% of c-Kit function in these 
animals, but was still able to result in impaired β-cell growth and function even at 8 
weeks of age (Krishnamurthy et al., 2007). As predicted, the minor reduction of c-Kit 
coincided with a small decrease in VEGF-A accumulation in culture medium (Figure 
3.13C). Analysis of Hif-1α and Vegf-A transcript levels showed a trend toward decrease, 
but did not reach significance (Figure 3.13A). Taken together, these results suggest that 
there was transfection inefficiency, possibly due to the transient transfection technique 
utilized and, possibly, requirement of a longer time-point to see an effect on VEGF-A 
signaling. Similar to the SCF-treated conditions, it was found that siRNA-treated cells 
had slightly decreased levels of intracellular VEGF-A, however it did not reach statistical 
significance (Figure 3.13B), reflected in morphological analysis of VEGF-A and insulin 
double immunofluorescence staining (Figure 3.14BC).  It has indeed been demonstrated 
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that, while VEGF-A is regulated by HIF-1α production, Von Hippel-Lindeau tumor 
suppressor (pVHL) is able to ubiquitinate and degrade HIF-1α by its E3 ubiquitin-protein 
ligase activity, an oxygen-dependent process (Manalo et al., 2005). Since c-Kit siRNA-
treatment does not affect oxygen and, instead, suppresses HIF-1α production by c-Kit 
inactivation, it is possible that pVHL production is dysregulated and, thus, HIF-1α 
degradation is less profound under these conditions. It has also been shown that VHL-
high hemangioblastomas are found to be positive for stem cell markers such as CD34 and 
CD133 (Chan et al., 2005). Since pVHL levels were not examined in this work, it would 
be beneficial to determine whether a reduction in c-Kit could affect pVHL production 
and be responsible for the minor change observed in regard to Hif-1α and Vegf-A 
transcript levels. It should be noted, however, that upon gross examination, both insulin 
and VEGF-A stain intensity seemed to be lower in the siRNA-treated group (Figure 
3.14A), but this did not transfer to a significantly reduced level of VEGF-A protein. 
Levels of phosphorylated Akt, phosphorylated mTOR, phosphorylated p70S6K, and 
phosphorylated NfκB were all significantly reduced followed siRNA treatment (Figure 
3.15). These changes were reflected further downstream with significant decreases in 
Gsk3β phosphorylation, and total β-catenin levels (Figure 3.16). Previous studies have 
noted decreases in many of these proteins in vivo, using the heterozygous c-Kit 
knockdown model (Krishnamurthy et al., 2007; Feng et al., 2012A). This further suggests 
that after extended siRNA knockdown time, it is possible that these changes would 
manifest as decreases in the final product, VEGF-A, or its key mediator, HIF-1α. p38 
MAPK phosphorylation was not significantly different when compared to controls 
(Figure 3.16) suggesting again that the transfection time/efficiency was not sufficient to 
elicit an inhibitory response from c-Kit knockdown. It has been reported that p38 MAPK 
and p42/44 MAPK are involved in regulating intracellular calcium levels by PKC, which 
is largely related to secretion rate of angiogenic factors (Ito et al., 1998; Takahashi et al., 
2001). Since p38 MAPK was reduced by ~54%, and p42/44 MAPK was not examined in 
the siRNA study, it’s possible that insufficiently reduced activation of these signaling 
molecules resulted in only minor changes to VEGF-A production and secretory capacity. 
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4.7 Limitations of the Study and Methodology 
While this study highlights a correlation between c-Kit activity and modulation of the 
angiogenic factor VEGF-A, there are several drawbacks and limitations to this work. 
First, the INS-1 cell line used in this study is a good model for pancreatic β-cells, but are 
still physiologically different. This cell line is able to attain an 8-fold maximal insulin 
secretion response to glucose and has only marginal increases in cAMP levels in response 
to glucose (Yang et al., 2004). Furthermore, INS-1 cells have been shown to reach a 
plateau of insulin secretion once they reach a high level of confluence, suggesting that if 
cell density is affected by treatment, it may affect insulin secretion and cell health, 
confounding experimental results (Hectors et al., 2013). INS-1 cells, by their nature, lack 
endothelial cells to create a microenvironment, which results in a loss of feedback that β-
cells would receive following changes in hormone secretion, especially since they lack 
receptors for VEGF-A, the hormone of interest (Inoue et al., 2002). In order to determine 
function of VEGF-A in vessel formation, it would be possible to co-culture the INS-1 cell 
line with an endothelial cell line, such as human microvascular endothelial cells 
(HMECs) or human umbilical cord endothelial cells (HUVECs), with or without 
exogenous SCF stimulation, and monitor their effect on endothelial cell organization, 
fenestration and caveolae formation, modulation of cell adhesion molecules, VEGF-A 
secretion changes, and antiangiogenic factor secretion (e.g. thrombospondin-1). 
Secondly, while it was established that c-Kit and VEGF-A are both expressed in this cell 
population, an immunoprecipitation was not performed and thus, a direct link cannot be 
established between the two proteins, leaving room for the examination of other factors 
that may be responsible for the changes in VEGF-A levels observed. In particular, 
insulin-like growth factor 1 and 2 (IGF-1/2) signaling has been implicated in VEGF-A 
regulation and angiogenesis, specifically by HIF-1α induction, but were not examined in 
this work (Stoeltzing et al., 2003; Bjorndahl et al., 2005; Ma et al., 2006). Furthermore, 
insulin signaling has been shown to play a role in the modulation of VEGF-A in a variety 
of tissue types, and the insulin receptor is thought to crosstalk with c-Kit, thus, opening 
another potential avenue for research (Lu et al., 1999; Hale et al., 2013). It is of particular 
interest to examine the involvement of these signaling pathways to investigate possible 
cross-talk with c-Kit and more insight into how angiogenic signaling is controlled in β-
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cells. Finally, the c-Kit siRNA transfection showed minimal knockdown of c-Kit, its 
downstream signaling molecules and VEGF-A, thus dosage and treatment time need to 
be reexamined to provide a more efficient knockdown and perhaps a more potent effect 
on VEGF-A production and release. 
4.8 Conclusion and Future Direction 
Understanding the mechanisms that regulate VEGF-A production and release are 
essential in reaching the goal of manipulating their activity to recover disrupted islet 
vasculature following trauma or transplant. This study has demonstrated that c-Kit 
activation, by SCF stimulation, is able to increase the proteins and targets of the 
PI3K/Akt/mTOR axis in order to have transcriptional effects on a functional model of β-
cells in vitro. The results of this study suggest that siRNA-mediated knockdown of c-Kit 
is able to attenuate this effect to some extent, but further work with, perhaps, a modified 
transfection procedure would yield more conclusive results. More importantly, in order to 
confirm that SCF/c-Kit interaction plays an essential role in mediating VEGF-A 
production, combining siRNA-mediated c-Kit knockdown and SCF stimulation should be 
considered to determine whether knockdown following stimulation would attenuate the 
PI3K/Akt/mTOR-mediated VEGF-A production.  Furthermore, this study was able to 
demonstrate that inhibition of c-Kit’s downstream targets was indeed able to attenuate 
VEGF-A production, but analysis of RNA and protein in these inhibition studies would 
be necessary to confirm that the pathway used to regulate VEGF-A expression is, in fact, 
PI3K/Akt/mTOR (Figure 4.1). Additionally, it should be noted that c-Kit is able to signal 
other pathways and, to fully understand its effect on VEGF-A modulation, changes in 
pathways such as Wnt signaling and MAPK pathways should be further examined. Wnt, 
specifically, is able to stimulate β-catenin nuclear translocation, and has been shown to 
play a role in blood cell formation in hematopoietic stem cell populations lacking c-Kit 
(Trowbridge et al., 2010). Thus, stimulation of cultured INS-1 cells by exogenous Wnt 
with and without c-Kit blockade would be an interesting avenue of research to pursue in 
the future. Finally, future work should take these concepts and apply them to primary 
islet cell culture studies and in vivo models in order to determine the effect of c-Kit 
activation and knockdown on a living system in regard to vascular changes, changes in 
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protein signaling, and possibly the effects of VEGF-mediated inflammatory responses. A 
thorough study of c-Kit-mediated VEGF modulation will allow researchers to work on 
developing cell-based therapies for revascularization of pancreatic islets. 
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Appendices 
Appendix I – Phase contrast Images Prior to and Following Inhibitor Treatment 
 
Phase-contrast images demonstrating consistant cell confluency between controls and 
cells treated with (A) Lys294002 at varying concentrations with or without SCF, or (B) 
rapamycing at varying concentrations with or without SCF. 
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(A) The melting curves and (B) derivative metling curves of Hif-1α, VEGF-A, and 18S 
show that qRT-PCR assays have amplified the target sequences with high specificity. 
Hif-1α VEGF-A 
18S 
Appendix II – The Melting Curves and Derivative Melting Curves of qRT-PCR Products 
(A) (B) (A) (B) 
(A) (B) 
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Appendix III – Classification 2 Laboratory Permit Summary 
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Appendix IV – Biosafety Approval 
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